# TB-500 (Thymosin Beta-4) slug: tb-500 · https://miscsubjects.com/a/tb-500 · tags: peptide, tb-500, thymosin-beta-4, disc · updated 2026-08-06T07:45:10.431Z Your body already makes the thing this vial is named after. It is a protein called thymosin beta-4, 43 amino acids long, and almost every cell you have releases it — platelets dump it into a fresh wound, and the cells that clean up damage make more of it. Its job is to hold loose actin, the material a cell builds its own skeleton out of, so the cell can change shape and crawl toward the injury. Here is the evidence state, and it decides how to read everything after it. Randomised trials of the seven-amino-acid fragment sold as TB-500: none completed, none running, none finished and unpublished. The number of people who have ever been given that fragment in a study, by any route, is nought, so there is no established dose for it, no measured blood level in a person, and no side-effect rate from a trial. One record on ClinicalTrials.gov names TB-500 — NCT07487363, first posted March 2026 — and its own public summary opens by saying it is a fictional example of a registry-style record. The controlled human evidence that does exist belongs to a different molecule, the 43-amino-acid parent protein thymosin beta-4, and it was given as eye drops or a skin gel: three completed dry-eye trials totalling 1,618 people, a nine-person dry-eye trial, an 18-person trial in a nerve-damaged cornea, and two 72-person skin-ulcer trials. Add the Chinese full-length programme and another 236 people have had the parent protein into a vein. None of that is tendon, ligament, muscle, fascia, cartilage or disc, and in twenty years no sponsor has registered a musculoskeletal trial of either molecule. The animal record is rats, mice, rabbits and horses, and its strongest single result is eight rats an arm with a stitched Achilles tendon. What has never been measured in a person is the thing in the vial. One disclosure, because it should change how you read the rest. The operator of this site has a commercial interest in compounds described here. That is a reason to weigh what is on this page against the sources it cites rather than against its tone, and every claim below carries the source that supports it for exactly that reason. What is sold as "TB-500" is not that protein. It is a seven-amino-acid piece cut out of the middle of it — positions 17 through 23 — with a chemical cap welded onto the front end. Written out it is Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln, or Ac-LKKTETQ for short. The studies on the vendor page were nearly all run on the 43-amino-acid protein. The powder in the vial is nearly always the seven-amino-acid piece. That is the single most useful fact on this page, so it goes first. Everything else — the dosing arithmetic, the horse blood levels, the rat tendons, the anti-doping ban, the cancer numbers, what 31 people who injected it say happened to them — reads differently once you know the evidence and the product are two different molecules. ## What is breaking down, and what would have to be built back Take the two injuries that bring people here. A tendon is rope. Type I collagen fibres, laid down in parallel, bundled, and anchored into bone. It goes wrong slowly: the fibres lose their parallel order, the cells inside stop laying down good collagen and start laying down disorganised patch material, and tiny vessels grow in where they do not belong while the tissue overall stays starved of blood. That last part is the whole problem. A tendon has very little blood supply, so the cells and oxygen needed to rebuild it arrive slowly, and the repair loses the race against the next load you put through it. A disc in your spine is worse. The soft centre of the disc holds water under pressure; the tough outer ring contains it. With age and load the centre dries out, the ring cracks, the height drops, and the joints above and below start taking force they were not built for. A disc has almost no blood supply at all in its middle — nutrients seep in slowly through the bone above and below it. Nothing in the body repairs more slowly than the middle of a disc. [[degenerative-disc-disease|What degenerating discs actually do]] and [[herniated-disc|what a herniation actually does]] are covered separately. So the chain that breaks tissue down looks like this: load exceeds repair, the cells switch from building rope to building patch, blood supply stays too thin to feed either, the patch scars instead of remodelling, and the tissue ends up weaker — so the same load now breaks it faster. Anything that would build it back has to hit one of five links. This is the frame to hold every claim below against. | Link in the chain | What would have to happen | Does the evidence reach it | |---|---|---| | Blood supply | more small vessels feeding the injury | strong for the 43-amino-acid protein in animals, and the seven-amino-acid piece is the part that does it | | Cells arriving | repair cells crawl into the damage instead of sitting at the edge | strong in a dish and in rodent skin, never measured in a human tendon | | Collagen quality | new rope laid parallel, not patch laid crossways | one rat Achilles study, eight animals in the arm | | Less scar | fewer of the contracting cells that turn repair into scar | real for the full protein, and it runs through a piece the vial cannot make | | Inflammation settling | fewer inflammatory signals, so repair can start | shown for the full protein, not for the fragment | ## The vial and the studies contain different molecules Two products sit side by side on the same shelf at the same 10 mg strength — one labelled "TB-500", one labelled "TB-500 / Thymosin Beta-4" — and nothing on either label tells you which molecule is inside. This is not a technicality. | | Thymosin beta-4 (the natural protein) | "TB-500" as sold | |---|---|---| | Length | 43 amino acids | 7 amino acids (positions 17–23) | | Sequence | the whole protein | Ac-LKKTETQ | | Weight | ~4,963 daltons | 889.01 daltons | | Front end | bare | capped with an acetyl group | | Catalogue numbers | recombinant or synthetic full-length | CAS 885340-08-9, UNII QHK6Z47GTG, PubChem CID 62707662 | | Tested in people | yes — eye drops, skin gel, heart | never, by any route | | Can it release Ac-SDKP | yes, cut off the front end | no, it comes from the wrong part of the protein | | Official drug name | recombinant human thymosin β4 | it does not have one | Where the fragment came from is documented. In 2003 a group cut the protein apart looking for the smallest piece that still grew new blood vessels, and found it: those seven amino acids, and nothing shorter. Peptides missing the seven were dead. The seven on their own worked at about 50 nanomolar. Adding loose actin at 5 to 50 nanomolar switched the effect off completely, which proves the activity comes from grabbing actin rather than from docking into a receptor. [[embed:source:s1]] That is the honest origin story. The fragment is real, it does one real thing, and one thing is not the same as everything the parent protein does. ## A regulator wrote the mismatch down in July 2026 The Pharmacy Compounding Advisory Committee briefing package is the only document from a government agency that examines TB-500 as a substance. It says in plain terms that the two are not interchangeable, and it names the marketing error. [[embed:source:s22]] Three findings in that package change how everything else reads. **Nobody has been given it and measured.** The agency searched the published literature through March 2025 and reports that "no articles were found in which TB-500 was administered to humans." The people who nominated it supplied no clinical data and no record of anyone taking it, by any route. The agency's safety verdict is the word "unknown" — not clean, not dangerous, unknown. **The cap on the front end is not a detail.** The wound-healing papers vendors point at used the *uncapped* seven amino acids, LKKTETQ. FDA states that capping the front end "irreversibly alters their charge, hydrophobicity, and size," and that what the uncapped version does "cannot be directly extrapolated" to TB-500. Change the electrical charge and the water-repelling behaviour of a molecule whose entire job is sticking to another molecule, and you have changed the thing that matters. **The one time anybody tested TB-500 itself in a dish, it did nothing.** In a scratch test — you scrape a line across a sheet of skin-building cells and time how fast they close it — TB-500 free base "appeared to be devoid of wound-healing properties." Its breakdown product, capped LKKTE, at 50 micrograms per millilitre did close the scratch by a small but real amount. That leaves open the possibility that TB-500 is a delivery form for a shorter piece. Nobody has tested that either way. The same package records that the nomination itself carried a molecular formula that was wrong and a CAS number matching neither the free base nor the acetate salt. It also records where TB-500 actually came from commercially: a 2011 veterinary preparation sold to make racehorses and racing greyhounds perform better. ## Seven amino acids are enough to pull one lever The proposed mechanism runs in five steps. None of it is special injury machinery. It is the ordinary business of a cell changing shape, happening where tissue is being rebuilt. 1. **Holding loose actin.** The protein grabs free actin building blocks, one molecule to one molecule. A held block cannot join a growing strand, so the cell keeps a stock of ready parts instead of a stiff finished mesh. 2. **Releasing it on command.** Letting those blocks go where and when the cell wants lets it extend a strand in one direction and push. Holding is not blocking. It is stockpiling, and the stockpile is what makes movement in a chosen direction possible. 3. **Crawling.** A cell that can build a leading edge crawls. Skin cells crossed a filter two to three times faster with as little as 10 picograms of the protein present. The cells that line blood vessels do the same thing. 4. **New blood vessels.** Those seven amino acids are the piece that does this, and this is the only step where the fragment is the active part rather than a bystander. Vessel-lining cells crawl, sprout, and form tubes. 5. **Inflammation settling down.** The full 43-amino-acid protein reduces the number of inflammatory cells at a wound and turns down three inflammatory signals — TNF-alpha, interleukin-1β and interleukin-6. [[embed:source:s28]] Steps 3 and 4 were measured together in the original rat wound work. Applied to the skin or injected into the belly cavity, the full protein grew the skin surface back over the wound 42% faster at four days and 61% faster at seven, with more collagen and more vessels in the treated wounds than in the salt-water controls. [[embed:source:s2]] Step 4 is the step that matters for the tissue you are worried about. Tendon, ligament, the sheet of tissue around muscle, and the disc in your back all share one problem: not enough blood. A mechanism aimed at growing vessels is aimed at the actual bottleneck. That is a good argument on paper. It is also where the argument stops, because nobody has grown a vessel into a human tendon with this and measured it. ## Why it gets run with BPC-157, and what happened when somebody tested that [[bpc-157|BPC-157]] and TB-500 are sold as a pair because their proposed mechanisms sit at different points in the same repair sequence. | | TB-500 / thymosin beta-4 | BPC-157 | |---|---|---| | What it grabs | the pool of loose actin building blocks | the grip machinery a cell uses to hold a surface (FAK and paxillin) | | How it reaches blood vessels | the seven-amino-acid piece makes vessel-lining cells crawl and sprout | raises the main vessel-growth receptor and the nitric-oxide pathway | | Level it acts at | supplying the cell's internal skeleton | grip and growth signals | | Tissue where it is best evidenced | cornea, skin wound (as the full protein) | rat tendon, ligament, gut | | Route used in the studies | on the surface, into the belly cavity, implanted locally | into the belly cavity, by mouth, locally | The theory is that one supplies the machinery for moving and the other supplies the signal telling cells where to move. It is coherent. It has been tested head to head exactly once, and the pairing failed. [[embed:source:s25]] Thirty-two male Sprague-Dawley rats, twelve weeks old, about 330 grams each, had the Achilles tendon cut through and repaired, then four weeks of injections into the belly cavity, in four groups of eight: BPC-157 at 10 micrograms per kilogram per day, TB-500 at 60 micrograms per kilogram per day, both together, or nothing. TB-500 on its own was the arm that reached statistical significance. Maximum load before the tendon failed: p < 0.05. Total Bonar score, which grades how normal the tissue looks under a microscope: p = 0.016. Movin score, a second grading scale: p = 0.017. A collagen stain showed the most orderly type I collagen in the TB-500 group. A protein stain found no real difference between groups in how much type I collagen was being made. And the combination "did not confer additional benefits compared to either agent alone." The synergy the pair is sold on did not appear in the one experiment that looked for it. ## The scar-tissue claim comes off a piece this fragment cannot produce A large share of the "breaks up scar tissue and adhesions" marketing traces back to Ac-SDKP, a four-amino-acid piece that calms inflammation and reduces scarring, released from the parent protein. Getting it out takes two enzymes working in order. First an enzyme called meprin-alpha cuts the front section of the protein into pieces under 30 amino acids long. Then a second enzyme, prolyl oligopeptidase, snips Ac-SDKP off. Neither enzyme can do it alone. [[embed:source:s29]] Now put the two facts side by side. Ac-SDKP comes off the **front end** of the protein. TB-500 is positions **17 to 23** — the middle. The four-amino-acid piece cannot be made from it at any dose, by any enzyme, in any tissue. Every scar-reduction claim built on Ac-SDKP belongs to the 43-amino-acid protein and does not carry over to what is in the syringe. There is a separate scar result for the full protein that does not depend on Ac-SDKP, and it is a good one. In rats, 100 micrograms of the protein delivered on days 2, 3 and 4 through implanted sponges produced wounds at day 14 with very few myofibroblasts — the contracting cells that pull a wound closed into a scar — and very few of their internal tension fibres. The collagen bundles were longer and thicker, and under polarised light they glowed the yellow-red of mature collagen where the untreated wounds glowed the green of immature patch material. Stopping cells from turning into myofibroblasts is the mechanism behind "repair instead of scar." [[embed:source:s27]] The 100 micrograms went into the wound on a sponge. It was the full protein. Neither of those matches a milligram injected into belly fat. ## Sort the whole literature by tissue and the tendon row is one rat study Somebody counted the entire field. A 2026 scoping review from an orthopaedics and rehabilitation group at the University of Utah screened 1,772 records and included 80 studies. [[embed:source:s10]] Their findings, in their own words: the evidence is "weighted toward mixed and in vitro designs, and most studies evaluated TB4 rather than TB-500"; "direct musculoskeletal tissue categories such as tendon, ligament, muscle, cartilage, and spine/intervertebral disc were comparatively sparse"; and "human evidence was concentrated in ocular/cornea and wound/skin/soft tissue settings, whereas direct TB-500 evidence was limited to a single included study." One study out of eighty tested the molecule that is actually sold. | Tissue | Best study | Species and model | n | Molecule | How it was given | Result | |---|---|---|---|---|---|---| | Tendon | Biçer 2026 (PMID 42542926) | rat, Achilles cut and repaired, 4 wk | 32 (8 per arm) | TB-500 | into the belly cavity, 60 µg/kg/day | load to failure up, p<0.05; Bonar p=0.016; adding BPC-157 gave nothing extra | | Tendon (cells) | Wu 2020 (PMID 31753373) | human stem cells from fat, on a woven scaffold | in a dish | full protein | released over 28 days from the scaffold | more crawling, more cells multiplying, cells turned into tendon cells | | Ligament | Xu 2013 (PMID 23523891) | rat, knee ligament cut through, 4 wk | not stated | full protein | 1 µg in 100 µL of fibrin glue, placed in the gap | even fibre bundles, significantly stronger repair | | Muscle | Tokura 2011 (PMID 20880960) | mouse, injured muscle plus cultured muscle cells | living animal and dish | full protein | the animal's own | the protein rises early after injury and pulls muscle cells toward the damage | | Skin wound | Malinda 1999 (PMID 10469335) | rat, full-thickness wound | not stated | full protein | on the skin and into the belly cavity | surface regrown 42% faster at 4 d, 61% at 7 d, 11% more wound contraction | | Scar | Ehrlich 2010 (PMID 20536458) | rat, implanted sponge, day 14 | not stated | full protein | 100 µg, days 2–4, into the wound | scar-pulling cells suppressed, mature collagen | | Heart | Bock-Marquette 2004 (PMID 15565145) | mouse, coronary artery tied off | not stated | full protein | belly cavity or into the heart, every third day | heart cells survived, pumping function improved | | Cornea | Sosne 2015 (PMID 25826322) | human, severe dry eye | 9 patients (18 eyes) | full protein, 0.1% | eye drops, 6×/day, 28 d | discomfort down 35.1%, p=0.0141; surface staining down 59.1%, p=0.0108 | | Cornea | Sosne 2022 (PMCID PMC9820614) | human, nerve-damaged cornea, Phase III | 18 (10 vs 8) | full protein, 0.1% | eye drops, 5×/day | day 29: 60% healed vs 12.5%, p=0.0656; day 43: 50% vs 0%, p=0.0359 | | Nerve | Morris 2010 (PMID 20627173) | rat, stroke from a clot | not stated | full protein | whole-body | better neurological recovery, nerve sheaths rebuilt, nerve fibres remodelled | | Disc and cartilage | — | — | — | — | — | nothing, for either molecule | [[embed:source:s19]] Read the "Molecule" column before you read the "Result" column. Ten of the eleven rows are the 43-amino-acid protein. ## The best tendon result that exists is eight rats an arm, injected into the belly That sentence deserves its own heading, because it is the single strongest piece of evidence in the world for the thing people buy TB-500 to do. It ran four weeks. It was a rodent. The dose went into the abdominal cavity, not under the skin. The authors call their own study "exploratory" and stop at calling both compounds "candidate adjuncts to tendon repair, pending dose-optimization and longer-term studies." Nothing in it supports a milligram-per-week injection under the skin of a person, and the authors do not claim it does. The delivery problem is out in the open in the tendon-engineering literature, which is itself a signal: the people who study getting this peptide into a tendon do not expect an injection into belly fat to do it. When the full protein was loaded into spun polymer yarns it released steadily over 28 days and pushed human stem cells taken from fat toward becoming tendon cells — they crawled more, multiplied more, and switched on tendon genes together. [[embed:source:s30]] The scaffold is the point. Somebody built a 28-day slow-release fibre to hold the peptide at the tendon, because holding it there is the hard part. ## The ligament study worked because the peptide was put in the wound The rat knee-ligament study gets summarised as "TB-500 heals ligaments." What it actually did was place 1 microgram of the full-length protein, carried in 100 microlitres of fibrin glue, directly into a ligament that had just been cut through. Local. Held in place by a carrier. One microgram. A different molecule. [[embed:source:s11]] The paper opens by noting that as of 2013 nobody had ever published on this protein in ligament repair at all. ## In muscle, your body already sends this signal after an injury The muscle result is not a treatment result, and it is worth understanding why. Injuring a muscle causes the muscle itself to make more thymosin beta-4 — in the fibres that are regenerating, and in the blood-cell-making cells that move into the damage. The protein then acts as a chemical attractant, pulling muscle precursor cells toward the injury. Both the ordinary protein and its oxidised form sped up closure and pulled cultured muscle cells across a gap. Precursor cells taken from adult muscle followed the oxidised form. [[embed:source:s26]] So the pathway is real in skeletal muscle, and your body switches it on by itself when you tear something. What has never been tested is whether adding more from outside improves a strain. No study has asked that question. ## Every controlled result in a person is an eye or a skin wound Here is the entire human record for the 43-amino-acid protein, sorted by tissue. None of it is muscle, tendon, ligament or disc. **Eyes — the only place the numbers turned positive.** A nine-patient dry-eye trial reported eye discomfort down 35.1% and surface damage staining down 59.1% against the vehicle drops. [[embed:source:s18]] [[embed:source:s45]] A Phase III trial in nerve-damaged cornea randomised ten patients against eight. Complete healing at four weeks was 60% versus 12.5%, p = 0.0656 — which misses the usual cutoff for calling a result real. At day 43 it was 50% versus 0%, p = 0.0359, which clears it. [[embed:source:s32]] Three completed Phase 3 dry-eye trials sit behind those: ARISE-1 with 317 patients, ARISE-2 with 601, and ARISE-3 with 700, the last finishing in October 2021. Total: 1,618 people. There is still no FDA approval. **Skin — completed, but safety was the question being asked.** The pressure-ulcer trial enrolled 72 patients on gel at 0.01%, 0.02% and 0.1% by weight, once daily for up to 84 days. The main question was safety and tolerance. Healing was a secondary question. [[embed:source:s3]] A matching 72-patient trial in leg ulcers from poor vein drainage completed on the same design. [[embed:source:s4]] [[embed:source:s5]] Two more were stopped early: one in the blistering skin disease epidermolysis bullosa, 30 patients, and one in corneal wounds in diabetic patients after eye surgery, 12 patients. [[embed:source:s13]] **Heart — withdrawn twice, then restarted in another country.** The animal finding that started the programme is specific: the protein forms a complex with two other proteins, PINCH and integrin-linked kinase, which switches on the survival signal Akt. After a coronary artery was tied off in mice, heart muscle cells survived better and the heart pumped better. [[embed:source:s31]] [[embed:source:s9]] The Phase 1 safety study in healthy volunteers was designed around single rising intravenous doses of 42 mg, 140 mg, 420 mg and 1,260 mg. It never enrolled anybody. The reason on the record: "Study never initiated due to contract manufacturing issues." [[embed:source:s34]] The Phase 2 heart-attack trial behind it was also withdrawn with zero patients enrolled. The only heart programme still producing human data is a Chinese full-length recombinant product called NL005: a Phase 1a in 54 healthy volunteers that established the highest tolerated dose, measured how fast the body cleared it, and checked whether the immune system made antibodies against it, then a Phase 1b in 30 people and two completed Phase 2 trials in heart attack. [[embed:source:s33]] Look at the dose scale in that withdrawn Phase 1 design. Milligram quantities of the full protein, dripped into a vein, in a hospital, under a protocol, are not the same object as 2.5 mg of a seven-amino-acid fragment injected under the skin of a belly at home — even though both are written in milligrams. ## One registry record names TB-500, and it says it is made up Search ClinicalTrials.gov for TB-500 and you get exactly one interventional record where the intervention is TB-500 itself: NCT07487363, "TBRIDGE-CV," sponsor listed as Hudson Biotech, first posted March 2026. Its summary reads, word for word: "This fictional study is an example of a ClinicalTrials.gov-style record." [[embed:source:s35]] It is a demonstration template. Its intervention description has an unclosed bracket. Its dose field says the levels "are not provided in this public example." Any page that cites NCT07487363 as proof TB-500 is in human trials is citing a placeholder — and that citation will keep appearing, because it is the only registry entry that looks like the thing people want to find. ## Nothing has ever been injected into a person and measured One row, stated plainly, because the tables above allow no other reading. There is no human trial of TB-500. None finished, none running, none registered. Every controlled human result belongs to the 43-amino-acid protein, given as eye drops or a skin gel, for dry eye, a nerve-damaged cornea, or a long-standing skin ulcer. For tendon, ligament, muscle, fascia, cartilage or disc, the count of human trials is zero for both molecules. If you are asking "is this proven for my tendon" — no. Not partly proven, not proven in a small way. The study has never been run. That is one row on this page, not the page. Everything else here is what is actually known. ## Mixing the vial, in numbers a syringe can read A freeze-dried vial holds a fixed mass of powder. The strength is whatever the water you add makes it, and the volume you inject follows from that. Insulin syringes are marked in units, where 100 units is 1 millilitre, so one unit is 0.01 mL. Take the common 10 mg vial and add **2 mL of bacteriostatic water**: - 10 mg ÷ 2 mL = **5 mg per mL** - 1 mL is 100 units, so 100 units holds 5 mg - **1 unit = 0.05 mg = 50 micrograms** | Dose you want | Volume | Units on a 100-unit insulin syringe | |---|---|---| | 250 mcg | 0.05 mL | 5 units | | 500 mcg | 0.10 mL | 10 units | | 1 mg | 0.20 mL | 20 units | | 2 mg | 0.40 mL | 40 units | | 2.5 mg | 0.50 mL | 50 units | | 5 mg | 1.00 mL | 100 units (the whole syringe) | Add 5 mL instead and you get 2 mg/mL. Now 1 unit is 20 micrograms, and a 2.5 mg dose is 125 units — more than one syringe holds, so a single dose takes two injections. That is why 2 mL is the practical fill for a 10 mg vial: it puts every commonly used dose inside one syringe. The mechanics, in order. Wipe the rubber stopper with alcohol and let it dry. Draw up the water. Angle the needle so the water runs down the inside glass wall instead of jetting straight onto the powder. Swirl until it goes clear. Do not shake. Shaking tears peptide molecules apart and makes them clump together, and clumping is the exact mechanism behind the immune-reaction concern further down this page. ## Every dose ever given in a study, and where yours would sit No dose-finding study of TB-500 exists. Not in any species, at any dose. The loading-then-maintenance schedule that circulates online has no source under it: no trial produced it, no blood-level study calibrated it, no regulatory filing contains it. The nomination sent to FDA specified a formulation — 3 mg/mL, "Subcutaneous and/or Intramuscular Injection" — and specified no dose at all. What does exist is every dose that has actually been given in a study, and the list is short enough to print in full. | Study | Molecule | Species | Route | Dose | Schedule | |---|---|---|---|---|---| | Biçer 2026, Achilles repair | TB-500 | rat | into the belly cavity | 60 µg/kg/day | daily, 4 weeks | | Ho 2012, blood levels | TB-500 | horse | under the skin | 10 mg total | one dose | | Rahaman 2024, scratch test | TB-500 | cells in a dish | in the culture fluid | 50 µg/mL | one exposure | | Xu 2013, knee ligament | full protein | rat | into the wound, in fibrin glue | 1 µg | once, at surgery | | Ehrlich 2010, sponge implant | full protein | rat | implanted locally | 100 µg | days 2, 3, 4 | | Philp 2003, punch wound | uncapped LKKTETQ | mouse | on the skin | 0.01% in buffer | day 0 and 48 h | | Bock-Marquette 2004, heart attack | full protein | mouse | belly cavity or into the heart | not fixed | every third day | | NCT00382174, pressure ulcers | full protein | human | gel on the skin | 0.01%, 0.02%, 0.1% by weight | once daily, up to 84 days | | NCT01393132, dry eye | full protein | human | eye drops | 0.1% solution | 6× daily, 28 days | | NCT02600429, cornea | full protein | human | eye drops | 0.1% solution | 5× daily, 43 days | | NCT00743769, heart (withdrawn) | full protein | human | into a vein | 42 / 140 / 420 / 1,260 mg | single rising doses, never run | Read the route column and count. Two doses in the entire record went under the skin: one of them was a horse, and the other does not exist. Every human dose ever given was put on a surface — a cornea or a wound bed — and none of them was TB-500. The one animal musculoskeletal study that came out positive on placement put 1 microgram directly into the wound in a glue carrier. The schedules people run use milligrams injected into belly fat and expect them to reach a tendon in the shoulder. Those are not the same treatment scaled up. They are different treatments. Three route facts are settled. There is no oral form that works, because your gut digests it. Under the skin and into the muscle are the routes the formulation was submitted for. Injecting into or right beside the injured structure — the route in the one positive animal result — is not the route almost anybody uses. ## Ten milligrams under the skin of a horse peaked at 0.08 nanograms per millilitre The only measurement of TB-500 in the blood of a living animal, in any species, comes from thoroughbred geldings given 10 mg of the free base under the skin. Blood concentration peaked at 0.05 to 0.08 nanograms per millilitre, somewhere between 60 and 120 minutes after the injection. Between 6 and 10 hours it could no longer be measured at all. It broke down by losing amino acids one at a time off the tail end: Ac-LKKTET, then LKKTE, then LKKT, then LKK, then LK. Two things follow from that, and both change how you would take it. **Dosing every three or four days has nothing behind it.** Schedules that space injections out are usually defended by saying TB-500 has a long half-life. A compound that cannot be detected in blood 6 to 10 hours after a 10 mg dose does not have a long half-life. Whatever else might justify spacing doses out, measured persistence in the blood is not it — and no half-life for TB-500, in any species, has ever been published as a number. **Sub-nanogram blood levels off a 10 mg dose is a very small exposure.** For scale: the concentrations at which this peptide and its breakdown products do anything measurable in a dish are in the tens of micrograms per millilitre. That is four to five orders of magnitude higher than what a 10 mg injection produced in a horse. ## The 28-day rule comes from the water, not from the peptide - Freeze-dried powder: keep at 2–8 °C, or freeze it for long storage. Keep it out of light. - Mixed with **bacteriostatic** water, which contains 0.9% benzyl alcohol as a preservative: 2–8 °C, commonly cited as good for about 28 days. That 28 days is the preservative's specification. It is not a stability figure anybody measured on this peptide. - Mixed with **sterile** water, no preservative: one use, discard after a single draw. - Do not freeze and thaw it once it is in solution. There are no pharmacopeial stability data for either form of TB-500. FDA's own finding is that TB-500 free base "is not physically and chemically well characterized," and that tests for contaminants, clumping, microbial contamination and bacterial endotoxin are missing from the public data and from vendor Certificates of Analysis. ## How long each measured effect actually took to appear Every timeline anybody can quote belongs to a study, and they cluster tightly. | What was measured | Time to effect | Study | |---|---|---| | Skin surface regrown over a wound | 4–7 days | Malinda 1999 (rat) | | Collagen maturing, scar-pulling cells suppressed | 14 days | Ehrlich 2010 (rat) | | Cornea healing | 29–43 days | NCT02600429 (human) | | Dry-eye signs and symptoms | 28 days | NCT01393132 (human) | | Ligament strength | 28 days | Xu 2013 (rat) | | Tendon load to failure | 28 days | Biçer 2026 (rat) | | Long-standing skin ulcer healing | 84 days | NCT00382174 (human) | The musculoskeletal readouts all sit at four weeks in rodents. Rat tendon repairs faster than human tendon, and the human version of that four-week endpoint has never been measured. Any statement about how long you should expect to wait is a rat's timeline stretched across a species gap, for a molecule the rat got into its abdominal cavity. There is a second problem with judging this by how you feel. Tendon problems get better on their own over months. That is the ordinary course, with no treatment at all. If you improve on that timescale you cannot separate the compound from time, from having backed off the load, and from everything else that changed in the same window. ## The cancer objection has real numbers behind it The vessel-growing and cell-crawling machinery that would plausibly help a healing tendon is the same machinery a tumour uses to grow and spread. That is not a hypothetical. It has been measured in living animals. [[embed:source:s20]] Forcing a melanoma cell line to overproduce thymosin beta-4 gave a mean 2.3-fold increase in how far the cells crawled (95% CI 1.9–2.7, p<.001), a mean 4.4-fold increase in blood vessels inside solid tumours (95% CI 3.3–5.5, p<.001), and roughly four times as many tumour deposits in the lungs — 46.7 against 10.9. The authors concluded that thymosin beta-4 may drive tumour spread by switching on cell crawling and new vessel growth. The paper shares an author with the wound-healing and vessel-growth work. The helpful finding and the harmful finding come from the same laboratory and the same mechanism. That is not a scandal. It is what an honest mechanism looks like when you follow it in both directions. Three qualifications, all of them real. - The experiment used a virus to force a melanoma line to overproduce the protein. It did not give a seven-amino-acid fragment at the doses a person injects. It establishes that the risk is mechanically plausible and open. It does not establish a proven human hazard. - The literature runs both ways and depends on the cancer type. In multiple myeloma, this protein behaves as a tumour suppressor, and lower levels of it predict a worse outcome. [[embed:source:s21]] - No cancer-causation study of TB-500, in either form, has ever been run. FDA states that outright. The defensible position is a specific exclusion, not a ban on the compound. Active cancer, or a significant cancer history, is a reason not to use this — because the risk is unmeasured in the direction that would hurt you and the benefit is unproven. That is a bad trade regardless of how the mechanism eventually resolves. The wider literature supports that framing rather than either extreme. The protein is reported to help liver tumours in children spread, and to drive colon cancer cells to crawl through a specific signalling route, while in multiple myeloma losing it predicts a worse course. The effect depends on the tumour, which is exactly why no blanket reassurance is available in either direction. ## What is in the vial has never been tested for the things that could hurt you Separate from cancer, and specific to injecting a substance nobody has characterised: | Risk | Where it stands | |---|---| | The immune system reacting to it | FDA: TB-500 "may pose a significant risk" here, "potentially amplified by aggregation as well as potential peptide-related impurities" | | Peptide contaminants | not characterised in public data or in vendor Certificates of Analysis | | Bacterial endotoxin | not tested in public data | | Clumped peptide | not tested in public data | | Microbial contamination | not tested in public data | | Cancer causation | no studies exist | | Reports of harm after sale | the FDA adverse-event database returned zero reports for TB-500 | The zero in that last row is not reassurance, and reading it as reassurance is the mistake this page most wants you to avoid. There is no legal human market for TB-500, so there is no channel through which a report could be filed. FDA's food and cosmetics system held two cases mentioning "blended TB-500 and BPC-157," with no safety assessment attached to either. No surveillance produces no data, and no data looks identical to safety if you do not check which one you are looking at. Nobody has published an independent purity or endotoxin audit of the consumer TB-500 market. Searching for one returns vendor pages claiming 99% purity and nothing that tested the claim. FDA arrived at the same place from the paperwork side: the nomination package supplied a molecular formula that was wrong and a CAS number matching neither form of the substance. That is what an uncharacterised material looks like on paper. The only safety information with any weight behind it belongs to the full-length protein, and even that is thin at whole-body doses. The one programme that has produced human immune-response and blood-clearance data for the protein given systemically is the Chinese recombinant product, whose Phase 1a in 54 healthy volunteers measured the highest tolerated dose alongside peak concentration, time to peak, total exposure, half-life, clearance rate and antibody formation. [[embed:source:s41]] Those numbers describe a 43-amino-acid recombinant protein dripped into a vein under a hospital protocol, and they are not published in the searchable literature. They do not describe the fragment, the route, or the setting in which TB-500 is actually used. ## Banned in sport at all times, and the wording names tendons The 2026 Prohibited List, in force from 1 January 2026, lists under section S2.3 — Growth Factors and Growth Factor Modulators — "Thymosin-ß4 and its derivatives e.g. TB-500." [[embed:source:s23]] Four details decide what that means for you. - **Prohibited at all times**, in competition and out of it. Using it in the off-season is still a violation. - It is a **Non-Specified Substance** — the harsher sanction tier, with no starting presumption that the penalty should be reduced. - The catch-all clause covers "other growth factors or growth factor modulators affecting muscle, tendon or ligament protein synthesis/degradation, vascularisation, energy utilization, regenerative capacity or fibre type switching." The exact reason you would take it is the exact behaviour the clause prohibits, written out in the rule. - "Other substances with similar chemical structure or similar biological effect(s)" are prohibited too, which sweeps in unnamed fragments and lookalikes. Enforcement is real, and it has hit the pairing specifically. The Canadian Centre for Ethics in Sport imposed a four-year ban on an athlete for BPC-157 and TB-500. The United States Department of Defense has adopted WADA categories S0 through S5, which puts service members under the same restriction. [[embed:source:s12]] Sanctions do not require a positive test. They can be imposed on an admission, on possession, or on a purchase record. If you are in a college programme, a national federation, an Olympic pathway, most professional leagues, or the military, that exposure exists whether or not anybody ever tests you. ## The July 2026 vote started a process, it did not change the status On 23–24 July 2026 the Pharmacy Compounding Advisory Committee voted 8 to 6, with one abstention, in favour of letting BPC-157, KPV and TB-500 be compounded — against FDA's own written recommendation that "a balancing of the criteria weighs against" listing them. [[embed:source:s24]] What that vote does and does not do: - It does **not** make TB-500 an approved drug. - FDA is **not bound** by the recommendation. - It starts a formal rulemaking cycle that realistically runs eight to twelve months. - As of this writing TB-500 is **not** on the 503A Bulks List and is not legally compoundable. No outsourcing facility has reported compounding it, and no pharmacy was found doing so. "The FDA just approved it" is wrong twice: there is no approval, and the rulemaking has not finished. ## Thirty-one people wrote down what happened to them, and the split is not what the marketing says Everything above this line is evidence. What follows is not, and it is counted anyway, because it is the only record of people using this for the reason you are reading about it. Thirty-one first-person accounts, posted publicly on X between January and August 2026. Each one was located by search and then re-checked independently by pulling the post back and comparing the full text and the timestamp. Three candidates failed that check and are not counted. Nobody in this set was randomised, blinded, or controlled. Nobody tested the powder before injecting it, so the actual substance is unknown in every case. People who improved are far more likely to post than people who did not, so the set is selected before you even read it. **The count: 17 said it helped. 8 said nothing happened. 6 had a reaction or got worse. Denominator 31.** Two of those 31 were treating a gut complaint rather than a musculoskeletal one. Drop those two and the split is 17 helped, 7 nothing, 5 worse, out of 29. There is one number that matters more than the split, and it is at the bottom of this section. Before the accounts themselves, the shape of them. The seventeen that helped cluster in shoulders and elbows run for four to eight weeks; the eight that reported nothing and the six that reported a reaction or a worsening are grouped under their own headings below, so you can read one group without reading all thirty-one. If you came here about a specific injury, the section titled injury by injury, what the record actually reaches is the one to read instead of these accounts: it sorts every tissue by what evidence exists in it, and for four of the seven rows the honest entry is none. No body-region tally is given for the thirty-one because the set is too small to divide without producing percentages that look like measurements, which is the failure this page spends its first section warning about. Every account below is quoted in the person's own words, with the handle, the date and a link to the original post. All of it is anecdotal. None of it is evidence. ### Seventeen said it helped The strongest reports come from shoulders and elbows, run for four to eight weeks. > "Ran BPC 500mcg twice a day and 6mg of TB500 every 5th day for 6-8 weeks. Healed my torn rotator cuff" — @PayHereSukka, X, 30 July 2026. Anecdotal. [[embed:source:w_7b0irg5j]] > "Slight tear of my rotator cuff. Surgery was a 5 month rehab timeline, instead I took bpc-157 and tb-500. Was back to full rotation in my shoulder and benching good weight by a month and a half!" — @GrantWest14, X, 10 January 2026. Anecdotal. [[embed:source:w_z5qnxkqk]] > "I was dealing with a nagging golfers elbow for over a year. Would be tender the to the touch after hitting balls. Within a week of taking shots the pain started to disappear. Months later its compmetely healed." — @ryalljohnny1989, X, 3 August 2026. Anecdotal. [[embed:source:w_bpr3c1ux]] > "I took it alongside TB-500 and it fixed my tennis elbow and was back to lifting also within two week." — @Das_Bear_, X, 29 June 2026. Anecdotal. [[embed:source:w_8aa4h36p]] Three of the seventeen were treating exactly the disc problem that may have brought you here, and all three describe substantial relief inside a month. > "I've been doing subcutaneous BPC TB+500 injections on both sides of the L5-S1 and a month in, the pain is dramatically less... the pain has been horrible for 6 years but this stuff really works. I don't wake up in awful pain anymore!" — @MithMuel, X, 30 June 2026. Anecdotal. [[embed:source:w_srfrp1td]] > "Blew up my back in 2017. L4/L5/S1 severe disc herniation. Doc diagnosed me with degenerative disc disease, told me to quit lifting... Found the Wolverine stack and within a month I was pain free." — @jasonsvoboda, X, 26 July 2026. Anecdotal. [[embed:source:w_t1lhudd5]] > "My lowest disc in the lower back is dried out, almost no fluid left, classic herniated disc... In June I ran BPC-157 and TB-500 for about 6 weeks... After 3-4 weeks it already felt better. Now after the cycle, zero pain in biceps and shoulder. Disc still needs physio and rest, but already much better." — @MuroCrypto, X, 31 July 2026. Anecdotal. [[embed:source:w_ionqqvc2]] Read that last one closely, because it is the most careful account in the whole set. He separates his shoulder result from his disc result, says the disc "still needs physio and rest," and adds "Don't know if it works the same for everyone, I'm no expert." That is what an honest anecdote looks like. Some report the effect arriving far faster than any tissue can rebuild — hours to days. That is a timescale for inflammation and pain signalling, not for collagen. > "Wednesday I woke up in severe pain in my L Leg. It was so bad I couldn't bear any weight... Peptides started in the afternoon. Leg 75% better in the evening... Saturday: Woke up 100% better." — @L0V3lsKeY, X, 2 August 2026. Anecdotal. [[embed:source:w_2m2r0oof]] > "BPC-157 + TB-500 vastly accelerated my recovery timeline, eliminated my knee pain two days after i started, and brought the swelling in my jaw down within the week" — @howdymary, X, 9 March 2026. Anecdotal. [[embed:source:w_7cn6wcbt]] Two days is not tissue repair. Whatever changed there, it was not new collagen. The remainder are knees, ankles, quads, and general joint pain. > "4 weeks 1mg bpc and then 4 weeks 2mg in knee. No acl or meniscus...knee has never felt better since before the injury years ago...also did tb500 twice a week total 4mg" — @caezcrypto1, X, 30 July 2026. Anecdotal. [[embed:source:w_4qf0wqtv]] > "I'm 95% sure that BPC-157 and TB-500 helped me heal from several injuries including my left knee and right ankle. I really thought I was going to need surgery for both." — @JonahLupton, X, 26 July 2026. Anecdotal. [[embed:source:w_albnpbru]] > "I tore both quad tendons in separate years, the first recovery had taken almost a year. After the second surgery... I added BPC-157 and TB-500. By month five, I was sprinting and jumping again" — @pepfessions, X, 3 August 2026. Anecdotal. [[embed:source:w_e9fjoshb]] > "After a week of BPC-157 (8 injections, 500mcg subcutaneous abdominal), persistent ankle tendon pain from a snowboarding injury a year ago is barely noticeable... Yesterday I added TB-500 (1 injection, 2mg) as well" — @jordaaash, X, 30 March 2026. Anecdotal. [[embed:source:w_dmeyan6q]] > "Have done a BLAST OF TB 500 and BPC -157 and KPV! Have serious shoulder tear! Blasted all three for 2 weeks!... Took my shoulder from barely joking a cupping hand to back in gym!" — @tj_underwood, X, 31 July 2026. Anecdotal. [[embed:source:w_1d35jifv]] > "My 70 yr old dad tore rotator cuff and I had him do 1mg (BPC) injected daily in 2 doses for 4 months with 2-3x/weekly TB500 @ 2.5mg/dose. Within a few weeks, he was lifting his arm totally above his head again and all pain was gone." — @_REDwave_2024, X, 20 May 2026. Anecdotal, and second-hand — the son is reporting his father's result. [[embed:source:w_8ed1wjyh]] > "Promise you peptides are No Joke, I used the wolverine stack (BPC-157 and TB-500) to alleviate lifelong shoulder and joint pains" — @BenWolf1425771, X, 3 August 2026. Anecdotal, and the same post links to a supplier, so treat it as promotional. [[embed:source:w_t3aoiz9r]] Two of these seventeen carry their own warning on their face. One reports the benefit disappearing about six weeks after stopping — which is the opposite of what tissue repair does. Repaired tendon does not un-repair when you stop injecting. > "All of the soreness, aches, and pains that disappeared while on BPC/TB500 returned after about 6 weeks for me. I start back on Monday" — @TheCaddieYardFL, X, 1 August 2026. Anecdotal. [[embed:source:w_ses7fkwk]] The other is @jordaaash above. He added TB-500 the day before he posted, after a week on BPC-157 alone, and the improvement he describes had already happened before the TB-500 went in. It is counted as a positive because the person counted it that way. It attributes nothing to TB-500. ### Eight said nothing happened These are not softer versions of the positives. They are people who ran it for weeks at ordinary doses and got no change at all. > "Did 3mg of BCP & 5mg of TB500 daily for two weeks into my elbow. It didn't do jack shit. This is my 3rd time trying peptides for various joint/tendon stuff and my 3rd time not noticing any improvement at all." — @prax1s_mm, X, 30 July 2026. Anecdotal. [[embed:source:w_avr26qqh]] > "Bpc and tb-500 did nothing for my elbow arthritis sadly. Used it for 6 weeks" — @replacementBux, X, 12 April 2026. Anecdotal. [[embed:source:w_hyq2egsc]] > "Age 62... I am very limited on what I can do at this point due to the severity of pain. I have been doing BPC 157 +TB 500 for 7 weeks, no improvement yet." — @ToddMil03223111, X, 9 July 2026. Anecdotal. [[embed:source:w_89es50pi]] > "I ran a heavy dose of klow into a heavy dose of bp-157 and tb500 for 2 months or more for my shoulder, did nothing, facing a shoulder replacement" — @moon25martin, X, 30 May 2026. Anecdotal. [[embed:source:w_fqd0nz38]] That last one is the harshest data point in the set: two months at heavy doses, no effect, still headed for a shoulder replacement. Somebody treating the same lower-back problem as the three positive disc reports got nothing at all. > "I'm trying it to see if it helps at all with inflammation for my lower back. L4/5 bulge and L5/S1 herniation. Bpc and Tb did nothing I could notice." — @HangryDBowman, X, 16 July 2026. Anecdotal. [[embed:source:w_s75yt6kt]] Three people saying a disc improved and one saying nothing changed, all treating an L5/S1 problem, none of them scanned before or after — that is a clean picture of exactly what uncontrolled reports can and cannot tell you. Two more report the effect as too small to matter rather than absent. > "I personally used bpc 157/ tb 500 combo for my shoulder issue. Barely moved the needle. 3/10." — @travfourr, X, 15 April 2026. Anecdotal. [[embed:source:w_lk8z70he]] > "I had some pain there and leading up to my bicep area. Didn't get much relief from bpc157/tb500." — @MittelstaedtTim, X, 11 June 2026. Anecdotal. [[embed:source:w_fkvglkvn]] One took an oral form for a gut complaint and got nothing, which is unsurprising given the peptide does not survive digestion. > "Just finished a bottle of oral liposomal BPC157+TB500 and it seems it did nothing :/ (hoping it would help heal my gut)" — @Gronnet, X, 26 April 2026. Anecdotal. [[embed:source:w_zj1lz4k4]] ### Six had a reaction or got worse These are the reports vendor pages do not carry, and the most informative account in the whole set is the first one. > "TB-500 made my shoulder left worse. I have bursitis and stopped TB and it's better. I was getting pain in left thumb and arm as well. I was pinning SubQ. I've used 3 different vendors who are legit. So I ruled out bad product. No issues with BPC-157." — @biotides, X, 7 July 2026. Anecdotal. [[embed:source:w_q1dsmvn0]] He had bursitis, the shoulder got worse on TB-500, it improved when he stopped, he had used three different suppliers so a bad batch is unlikely, and he had no problem with BPC-157. That is about as close as an uncontrolled self-report ever gets to isolating one variable. > "i ran bpc 157 for few weeks felt decent then add tb 500 hand and skeletal felt worse i discontinued it it was the blend version 20mg" — @cryptotray79, X, 14 June 2026. Anecdotal. [[embed:source:w_fgszb7lb]] > "I ran TB-500 for a shoulder injury and got a head rush that lasted maybe 20 minutes. Injection site was red for a day." — @UndergroundBio, X, 3 August 2026. Anecdotal. [[embed:source:w_wuu78tg1]] Three describe immune-type reactions — hives, itching. That is the exact category FDA flagged in advance, on the grounds that clumped peptide and manufacturing contaminants provoke it. > "Not my proudest moment, but after BPC-157 and TB-500 from the gray market, I got hives all over my body." — @stateofnomind, X, 10 March 2026. Anecdotal. [[embed:source:w_dwju43tz]] > "I took tb500 and bpc 157 mix for 3 days at 0.750 7.5 units on a 3mm needle i had some Hives show up on each side of love handles not the injection sites... Ive done research my self and stopped for now" — @GetterBankWest, X, 2 March 2026. Anecdotal. [[embed:source:w_nad31utv]] > "nothing moved the needle more re gut barrier symptoms than TB500. Until the development of an MCAS-like picture, it began to flair immune Sx: itching, hives from heat, etc." — @AmbrosesDrink, X, 4 August 2026. Anecdotal. [[embed:source:w_llsxbr8a]] ### Two of the thirty-one used TB-500 without BPC-157, and both are in the last group This is the number that matters. Twenty-nine of the thirty-one accounts ran TB-500 stacked with BPC-157, and several stacked a third and a fourth compound on top of that. Not one of those twenty-nine can attribute anything to TB-500. Every positive report in this set is a report about a combination. The two accounts that isolate TB-500 are @biotides, whose bursitis shoulder got worse and recovered when he stopped, and @UndergroundBio, who got a head rush and a red injection site. Both sit in the "worse" column. That is not evidence that TB-500 is harmful. Two reports settle nothing. It is a precise statement of how thin the isolated human experience with this compound actually is: out of 31 people who wrote down what happened, 2 took it on its own, and neither described a benefit. ### What these 31 reports can and cannot settle They can settle that people are running this at milligram doses for weeks, mostly stacked, mostly for shoulders, elbows, knees and lower backs, and that a substantial fraction of them believe it worked. They cannot settle whether it works. Nobody was blinded. Nobody imaged the injury before and after. Almost everybody changed something else in the same window — rest, physiotherapy, load reduction, a second compound, surgery. The conditions being treated improve on their own over the same timescale. And negative reports are systematically harder to find than positive ones, which means 17 out of 31 overstates the true positive rate by an unknown amount. Hold this section against the evidence sections above and the shape is clear. The self-reported record is large, warm, and confounded. The controlled record for this exact molecule, in this exact tissue, is a single study in eight rats. ## Injury by injury, what the record actually reaches | Your problem | Direct evidence in that tissue | Nearest real evidence | Where that leaves it | |---|---|---|---| | Tendon pain — Achilles, patellar, elbow | one 4-week rat study, 8 per arm, TB-500 into the belly cavity | Biçer 2026; Wu 2020 tendon cells in a dish | mechanism is plausible, one small animal result, nothing in people | | Ligament sprain | one rat knee-ligament study, full protein, placed in the wound in glue | Xu 2013 | positive, but a different molecule at 1 µg delivered locally | | Muscle strain or tear | none, only work on the body's own signal | Tokura 2011 | the pathway is real, adding more from outside is untested | | Disc injury, disc-related pain | none | the scoping review lists spine and disc as sparse | no evidence at all in this tissue | | Frozen shoulder | none | Ehrlich 2010 scar-cell suppression, rat sponge model | a scar-reduction argument only, and it belongs to the full protein | | Plantar fasciitis | none | tendon data by analogy | no evidence, treated as tendon pain by assumption | | Recovery after soft-tissue surgery | none in people | skin wound and heart animal work | untested | Two of those rows carry an extra warning. The frozen-shoulder and disc arguments both rest on reducing scar, and the strongest scar-reduction mechanism in this literature runs through Ac-SDKP — the piece the sold fragment cannot make. ## Every human study ever registered on this molecule Here is the whole clinical programme for the parent protein, with what actually happened to each trial. TB-500 appears in it once, as the fictional example. | NCT | Indication | Sponsor | Phase | Enrolled | Status | |---|---|---|---|---|---| | NCT00382174 | pressure ulcers | RegeneRx | 2 | 72 | completed | | NCT00832091 | leg ulcers from poor vein drainage | RegeneRx | 2 | 72 | completed | | NCT00311766 | epidermolysis bullosa | RegeneRx | 2 | 30 | terminated | | NCT00598871 | corneal wounds after diabetic eye surgery | ReGenTree | 2 | 12 | terminated | | NCT00743769 | intravenous safety, healthy volunteers | RegeneRx | 1 | 0 | withdrawn | | NCT01311518 | heart attack | RegeneRx | 2 | 0 | withdrawn | | NCT01393132 | severe dry eye | Michigan Cornea Consultants | 2 | 9 | completed | | NCT02597803 (ARISE-1) | dry eye | ReGenTree | 2/3 | 317 | completed | | NCT02974907 (ARISE-2) | dry eye | ReGenTree | 3 | 601 | completed | | NCT03937882 (ARISE-3) | dry eye | ReGenTree | 3 | 700 | completed | | NCT02600429 (SEER-1) | nerve-damaged cornea | ReGenTree | 3 | 18 | terminated | | NCT05555589 (SEER-2) | nerve-damaged cornea | ReGenTree | 3 | 70 planned | recruiting | | NCT04555824 | healthy volunteers, Phase 1a | Beijing Northland | 1 | 54 | completed | | NCT05485818 | heart attack | Beijing Northland | 2 | 62 | completed | | NCT05984134 | heart attack | Beijing Northland | 2 | 90 | completed | | NCT07586865 | heart attack | Beijing Northland | 2 | 189 planned | not yet recruiting | | NCT07487363 | TB-500, heart biomarkers | "Hudson Biotech" | 1/2 | 80 planned | self-declared fictional example | Four things fall out of that table. **No musculoskeletal indication has ever been registered.** Not tendon, not ligament, not muscle, not fascia, not disc. Not by any sponsor, in twenty years, for either molecule. That absence is not a hole in the search. It is the state of the field. **Both heart trials from the original sponsor were withdrawn before a single patient enrolled**, and the programme then moved to a different sponsor, a different country, and a recombinant full-length product. [[embed:source:s36]] **The published "Phase III" cornea result comes from a terminated trial.** SEER-1 stopped at 18 patients enrolled, and the ten-versus-eight comparison you read in the literature is that terminated trial's data. Its successor, SEER-2, is still recruiting toward 70. [[embed:source:s39]] [[embed:source:s42]] **Three completed Phase 3 dry-eye trials covering 1,618 patients have produced no approval.** ARISE-1 finished in 2016, ARISE-2 in 2018, ARISE-3 in October 2021. That is the largest and most mature dataset this molecule has, in the indication where it performs best, and it has not turned into a medicine anybody can buy. [[embed:source:s44]] [[embed:source:s40]] [[embed:source:s43]] The skin programme closed the same way — two trials completed with safety as the main question, two stopped early. [[embed:source:s37]] [[embed:source:s38]] ## What is solid, what is not, and the gap underneath both **Solid.** Thymosin beta-4 holds loose actin and controls how a cell builds its internal skeleton. Its seven-amino-acid actin-grabbing piece is the part that grows new blood vessels, working at around 50 nanomolar. The full protein closes rat skin wounds 42 to 61% faster, stops repair cells turning into the scar-pulling kind, works through integrin-linked kinase and Akt in injured heart muscle, pulls muscle precursor cells toward damage, and improves dry eye and nerve-damaged cornea in small controlled human trials. **Not solid.** That any of that heals a human tendon, ligament, muscle, disc or fascia. That the fragment sold as TB-500 does what the full protein does. That milligram-per-week injections under the skin reach an injured structure at a concentration where the mechanism runs. That the compound is safe in a person over any length of time, because that study has never been run. **The gap underneath both.** The evidence and the product are not the same substance. A regulator has written that down. The capped form has never been shown to do what the uncapped form does. And the one time anybody tested TB-500 itself in a dish, it did nothing. Every transfer of evidence from the 43-amino-acid protein to the seven-amino-acid fragment is an assumption, and it is the assumption the whole market stands on. The practical consequence is narrow and specific. Tendon pain from overuse, an impingement, and a partial tear are three different problems with three different treatment plans, and no peptide tells them apart. Getting the diagnosis right changes what you should do this week far more than anything in this vial does. The scoping review that counted this entire literature lands in the same place, in its own words: the evidence "remains unevenly distributed and largely preclinical, with limited human evidence directly relevant to musculoskeletal applications." *Not medical advice. TB-500 is sold for research use only, is not an approved drug, is not currently legal to compound, and is prohibited at all times in WADA-tested sport. Nothing here is a dosing or treatment recommendation.* The sibling objects for this page, each one inspectable on its own terms: [[embed:bpc-157]] [[embed:ara-290]] [[embed:wolverine-stack]] [[embed:wolverine-stack-ara-290]] [[embed:what-are-peptides-herniated-disc]] [[embed:bpc-157-vs-nsaids]] ## Sources 1. The actin binding site on thymosin beta4 promotes angiogenesis — https://pubmed.ncbi.nlm.nih.gov/14500546/ 2. Thymosin beta4 accelerates wound healing — https://pubmed.ncbi.nlm.nih.gov/10469335/ 3. Randomized, Double-Blind, Placebo-Controlled Study of Thymosin Beta 4 in Patients With Pressure Ulcers — https://clinicaltrials.gov/study/NCT00382174 4. Randomized, Double-Blind, Placebo-Controlled Study of Thymosin Beta 4 in Patients With Venous Stasis Ulcers — https://clinicaltrials.gov/study/NCT00832091 5. Thymosin beta-4 and venous ulcers: a European prospective, randomized study — https://pubmed.ncbi.nlm.nih.gov/17495250/ 6. Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial — https://pubmed.ncbi.nlm.nih.gov/26056426/ 7. Cardioprotection by systemic dosing of thymosin beta four following ischemic myocardial injury — https://pmc.ncbi.nlm.nih.gov/articles/PMC3843122/ 8. Thymosin beta4 is cardioprotective after myocardial infarction — https://pubmed.ncbi.nlm.nih.gov/17600280/ 9. Thymosin Beta-4 and TB-500 in Tissue Healing, Regeneration, and Musculoskeletal Repair: A Scoping Review — https://doi.org/10.3390/app16126202 10. Thymosin beta4 enhances the healing of medial collateral ligament injury in rat — https://pubmed.ncbi.nlm.nih.gov/23523891/ 11. TB-500 - Status, Risks, and Bans in Sport and Military — https://www.bscg.org/blogs/single/tb-500-status-risks-and-bans-in-sport-and-military 12. Thymosin beta4: potential to treat epidermolysis bullosa and other severe dermal injuries — https://pubmed.ncbi.nlm.nih.gov/31649007/ 13. TB-500 - Status, Risks, and Bans (BSCG) — https://www.bscg.org/blogs/single/tb-500-status-risks-and-bans-in-sport-and-military 14. Thymosin beta4 improves signs and symptoms of severe dry eye in a phase 2 randomized trial (Cornea 2015) — https://pubmed.ncbi.nlm.nih.gov/25826322/ 15. Thymosin beta4 improves functional neurological outcome in a rat model of embolic stroke — https://pubmed.ncbi.nlm.nih.gov/20627173/ 16. Role of thymosin beta4 in tumor metastasis and angiogenesis (JNCI 2003) — https://pubmed.ncbi.nlm.nih.gov/14625258/ 17. Thymosin beta4 has tumor suppressive effects in multiple myeloma — https://pubmed.ncbi.nlm.nih.gov/19833631/ 18. FDA Briefing Document, Pharmacy Compounding Advisory Committee — TB-500-Related Bulk Drug Substances (TB-500 free base and TB-500 acetate) — https://www.fda.gov/media/193349/download 19. World Anti-Doping Code International Standard — Prohibited List 2026, section S2.3 — https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf 20. FDA Panel Votes to Loosen Restrictions for Four Peptides — https://www.pharmexec.com/view/fda-votes-loosen-restrictions-four-peptides 21. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study — https://pubmed.ncbi.nlm.nih.gov/42542926/ 22. Muscle injury-induced thymosin β4 acts as a chemoattractant for myoblasts — https://pubmed.ncbi.nlm.nih.gov/20880960/ 23. Thymosin beta4 enhances repair by organizing connective tissue and preventing the appearance of myofibroblasts — https://pubmed.ncbi.nlm.nih.gov/20536458/ 24. The Role of Tβ4-POP-Ac-SDKP Axis in Organ Fibrosis — https://pmc.ncbi.nlm.nih.gov/articles/PMC9655242/ 25. The anti-inflammatory peptide Ac-SDKP is released from thymosin-β4 by renal meprin-α and prolyl oligopeptidase — https://pubmed.ncbi.nlm.nih.gov/26962108/ 26. Electrospun thymosin Beta-4 loaded PLGA/PLA nanofiber/microfiber hybrid yarns for tendon tissue engineering application — https://pubmed.ncbi.nlm.nih.gov/31753373/ 27. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair — https://pubmed.ncbi.nlm.nih.gov/15565145/ 28. 0.1% RGN-259 (Thymosin β4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial — https://pmc.ncbi.nlm.nih.gov/articles/PMC9820614/ 29. Safety and Efficacy Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction (NL005) — https://clinicaltrials.gov/study/NCT05485818 30. A Phase 1 Safety Study of the Intravenous Administration of Thymosin Beta in Healthy Volunteers — https://clinicaltrials.gov/study/NCT00743769 31. TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD — 'TBRIDGE-CV' [self-declared fictional example record] — https://clinicaltrials.gov/study/NCT07487363 32. A Study of the Safety and Efficacy of Injectable Thymosin Beta 4 for Treating Acute Myocardial Infarction — https://clinicaltrials.gov/study/NCT01311518 33. A Phase 2 Study on Effect of Thymosin Beta 4 on Wound Healing in Patients With Epidermolysis Bullosa — https://clinicaltrials.gov/study/NCT00311766 34. A Phase 2 Study of the Safety and Efficacy of Thymosin Beta 4 for Treating Corneal Wounds — https://clinicaltrials.gov/study/NCT00598871 35. Assessment of the Safety and Efficacy Study of RGN-259 Ophthalmic Solutions for Neurotrophic Keratopathy: SEER-1 — https://clinicaltrials.gov/study/NCT02600429 36. Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-2 — https://clinicaltrials.gov/study/NCT02974907 37. A Phase 1a Study of Thymosin Beta 4 in Healthy Volunteers — https://clinicaltrials.gov/study/NCT04555824 38. Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2 — https://clinicaltrials.gov/study/NCT05555589 39. Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-3 — https://clinicaltrials.gov/study/NCT03937882 40. Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-1 — https://clinicaltrials.gov/study/NCT02597803 41. Comparative Study of Thymosin Beta 4 Eye Drops vs. Vehicle in the Treatment of Severe Dry Eye — https://clinicaltrials.gov/study/NCT01393132 42. X · @PayHereSukka · 2026-07-30 — https://x.com/PayHereSukka/status/2082956437056008230 43. X · @MuroCrypto · 2026-07-31 — https://x.com/MuroCrypto/status/2083184469956059529 44. X · @jasonsvoboda · 2026-07-26 — https://x.com/jasonsvoboda/status/2081426443024961838 45. X · @MithMuel · 2026-06-30 — https://x.com/MithMuel/status/2071802227342340531 46. X · @howdymary · 2026-03-09 — https://x.com/howdymary/status/2031137869285425498 47. X · @Das_Bear_ · 2026-06-29 — https://x.com/Das_Bear_/status/2071462119011492350 48. X · @ryalljohnny1989 · 2026-08-03 — https://x.com/ryalljohnny1989/status/2084312093067513939 49. X · @caezcrypto1 · 2026-07-30 — https://x.com/caezcrypto1/status/2082943665832374561 50. X · @L0V3lsKeY · 2026-08-02 — https://x.com/L0V3lsKeY/status/2083868515438666186 51. X · @tj_underwood · 2026-07-31 — https://x.com/tj_underwood/status/2083248032603107752 52. X · @jordaaash · 2026-03-30 — https://x.com/jordaaash/status/2038733749366755452 53. X · @pepfessions · 2026-08-03 — https://x.com/pepfessions/status/2084071774480736712 54. X · @JonahLupton · 2026-07-26 — https://x.com/JonahLupton/status/2081490976510468316 55. X · @GrantWest14 · 2026-01-10 — https://x.com/GrantWest14/status/2010124835264111079 56. X · @_REDwave_2024 · 2026-05-20 — https://x.com/_REDwave_2024/status/2057019155824652482 57. X · @BenWolf1425771 · 2026-08-03 — https://x.com/BenWolf1425771/status/2084389889303548201 58. X · @TheCaddieYardFL · 2026-08-01 — https://x.com/TheCaddieYardFL/status/2083641327833522639 59. X · @prax1s_mm · 2026-07-30 — https://x.com/prax1s_mm/status/2082901582627184835 60. X · @replacementBux · 2026-04-12 — https://x.com/replacementBux/status/2043445152849555478 61. X · @moon25martin · 2026-05-30 — https://x.com/moon25martin/status/2060514158739640718 62. X · @ToddMil03223111 · 2026-07-09 — https://x.com/ToddMil03223111/status/2075223118067433536 63. X · @HangryDBowman · 2026-07-16 — https://x.com/HangryDBowman/status/2077974266339803140 64. X · @travfourr · 2026-04-15 — https://x.com/travfourr/status/2044547711114895786 65. X · @MittelstaedtTim · 2026-06-11 — https://x.com/MittelstaedtTim/status/2064873594103222656 66. X · @Gronnet · 2026-04-26 — https://x.com/Gronnet/status/2048321787667103904 67. X · @biotides · 2026-07-07 — https://x.com/biotides/status/2074549220887941324 68. X · @cryptotray79 · 2026-06-14 — https://x.com/cryptotray79/status/2071013244072788255 69. X · @stateofnomind · 2026-03-10 — https://x.com/stateofnomind/status/2031391204232016324 70. X · @GetterBankWest · 2026-03-02 — https://x.com/GetterBankWest/status/2028322438984175693 71. X · @AmbrosesDrink · 2026-08-04 — https://x.com/AmbrosesDrink/status/2084497141234598355 72. X · @UndergroundBio · 2026-08-03 — https://x.com/UndergroundBio/status/2084421599072039066 --- # The Wolverine stack plus ARA-290 for a degenerating disc and sciatica: the evidence at every link slug: wolverine-stack-ara-290 · https://miscsubjects.com/a/wolverine-stack-ara-290 · category: peptides · tags: peptide, bpc-157, tb-500, ara-290, disc, sciatica, stack, wolverine · updated 2026-08-04T22:08:42.768Z A worn spinal disc with a burning leg is not one problem. It is a breakdown running in three separate places at once, and the reason people add ARA-290 to the two-compound Wolverine stack is that the third place — the nerve fibres themselves — is the one the first two compounds do not touch. The evidence state, before the argument. No study in any species has ever given all three compounds together, so the number of people or animals that have taken this stack under measurement is nought. One at a time the three are nothing like each other. ARA-290 has six human studies and 132 people who received the active compound; three of the six missed their main endpoint, the positive results cluster in one disease, sarcoidosis, and not one of the six enrolled a person with a back problem. BPC-157 has five published human studies covering about 130 people, none of them a finished controlled trial in a torn or worn tissue. The seven-amino-acid fragment sold as TB-500 has no human study at all and no established human dose. Two entries were filed on ClinicalTrials.gov in February 2026 by one sponsor, Hudson Biotech: NCT07437547, a 120-person randomised, double-blind, placebo-controlled hamstring trial marked recruiting, and NCT07487363, which names TB-500 and whose own public summary states that it is a fictional example of a registry record. Neither has reported anything. The animal record behind the disc argument is rats, mice and rabbits, and the one experiment that ever combined two of the three found the pair beat neither compound on its own. What has never been measured in a person: any of the three against a squeezed nerve root or a worn disc, and all three together in anything alive. One disclosure, because it should change how you read the rest. The operator of this site has a commercial interest in compounds described here. That is a reason to weigh what is on this page against the sources it cites rather than against its tone, and every claim below carries the source that supports it for exactly that reason. This page sets out what is breaking down, what makes it break down faster, what each of the three compounds is proposed to build back, and how strong the evidence is at every single link. The grades differ enormously between links, and the strongest evidence in the whole stack sits on the compound most people leave out. ## Three things break down in a worn disc, and they break down in order **The disc dries out.** The soft centre of a spinal disc is mostly water, held there by a large sugar-and-protein molecule called aggrecan that acts like a sponge. At birth that centre is about 90% water. By 60 it is closer to 70%, because the aggrecan gets chopped up and washed out. Less water means less pressure inside, and a disc that cannot hold pressure cannot spread load. **The outer ring tears.** As the centre flattens, load transfers to the tough fibrous ring around it. That ring is not built to take the load directly, so it splits — small cracks first, then tears that run through to the outside. That is how a worn disc becomes a bulging or herniated one. **The chemistry turns hostile, and nerves grow in.** Disc cells under load start pumping out two inflammatory signals, TNF-alpha and IL-1beta. Those signals do three things at once. They raise the enzymes that chew up the disc's own scaffolding while lowering the proteins that block those enzymes, so breakdown outruns building. They irritate any nerve root nearby. And they coax pain nerve fibres to grow into a disc that normally has none in its centre at all. That third step is why worn and painful are different conditions. Plenty of badly degenerated discs never hurt. What makes a worn disc a painful one is chemistry, not the wear. [[embed:degenerative-disc-disease]] ## The reason the disc cannot fix any of it The spinal disc is the largest structure in the body with no blood supply of its own. Nothing feeds it directly. Nutrients seep in slowly through the bony end plates above and below, and those plates stiffen and calcify with age, so the supply gets worse exactly as the demand rises. Every tissue that heals well heals because blood brings oxygen, raw material and repair cells. The disc gets almost none of that. This single fact governs everything that follows: it is why the breakdown mostly runs one way, why swallowed supplements struggle to reach the tissue, and why any serious attempt at rebuilding has to solve the blood supply before anything else can matter. It is also why BPC-157 — a compound whose main proposed action is growing new blood vessels into damaged tissue — is the one people reach for, and why that reach has never been tested in a disc. ## What speeds the breakdown up, and which of those you control Most of what drives disc breakdown is fixed: age, the genes you have, injuries you already had. Two are not fixed, and both have better evidence behind them than any compound on this page. **Body weight.** A Mendelian randomisation analysis — the study design built specifically to separate cause from correlation, by using inherited genetic variation as the exposure — found that higher body mass index raises the odds of disc breakdown, of low back pain, and of sciatica. That is causal-grade evidence, which is a higher grade than anything supporting any of the three compounds here. **Smoking.** Nicotine narrows the small vessels feeding a tissue that is already starved of blood, and it is directly toxic to disc cells, cutting their repair activity. For a structure whose central problem is nutrition, that is the worst possible input. The widely repeated line that one pound of body weight equals four pounds on the spine is not a measured law. The genuine four-to-five-fold load spikes recorded inside living discs come from bending and lifting — the leverage of the trunk — not from a body-weight multiplier. ## Three compounds, three different parts of the problem, graded link by link This is the argument for the three-compound stack, stated as a table so each link can be attacked separately. The grades run A to F and are defined immediately below the table. | What is breaking down | The compound aimed at it | What that compound is proposed to do, in plain words | Strongest evidence for that link | Grade | What would prove this link wrong | |---|---|---|---|---|---| | No blood supply reaching the damaged tissue | BPC-157 | Grow new blood vessels into the injury by switching on the VEGF growth signal and the nitric-oxide system that widens vessels, so oxygen and raw material arrive | Rat Achilles tendon torn off the bone came back attached and mechanically stronger; cut ligament, crushed muscle and severed muscle-tendon join all healed faster than control | D | Counting vessels at the injury site in a controlled animal study and finding no difference against control | | Repair cells not reaching or not organising | TB-500 | Bind actin, the filament a cell builds and takes apart to change shape, so repair cells can crawl into the wound and lay ordered collagen instead of scar | Rat Achilles repair, 32 animals, 8 per arm, four weeks: higher load to failure than control, p < 0.05; best tissue score, p = 0.016; most ordered collagen under stain | D | Measuring how many repair cells arrive at the wound and finding no increase | | The nerve fibres themselves damaged and dying back | ARA-290 | Bind a receptor that only appears on tissue that is already injured, switching on a repair programme that regrows small nerve fibres, without raising red cell counts the way its parent hormone does | Randomised, placebo-controlled human trials. Corneal nerve fibre area rose 697 µm² above placebo at 4 mg a day for 28 days, p = 0.012, in 64 people with nerve fibre loss from sarcoidosis; nerve fibre density rose 2.6 fibres/mm² in the abnormal subgroup of a diabetic neuropathy trial, p = 0.02 | B | A randomised trial in a compressed nerve root showing no separation from placebo — which is the trial nobody has run | | The nerve root chemically irritated by TNF-alpha | BPC-157 and TB-500, weakly | Calm the inflammatory signalling around the root | Rodent anti-inflammatory models only. The strongest available test of this target in humans — blocking TNF-alpha with a monoclonal antibody at the nerve root — produced a null result against steroid | E | Already largely answered against, see below | | The displaced fragment physically pressing on the nerve | Nothing | No compound in this stack is claimed to move tissue | Not applicable | Not a claim | Any vendor asserting a peptide puts a disc back is making a claim with no mechanism behind it | | All three compounds together | — | The three steps at once | Nothing. No study in any species has given all three | F | Untested in every sense | ## The grades explained, so the table can be argued with - **A** — randomised, placebo-controlled human trial in the actual condition on this page. Nothing on this page holds an A. - **B** — randomised, placebo-controlled human trial in a different condition, with the target tissue measured directly. ARA-290 holds a B, on nerve. - **C** — controlled animal experiment in the target tissue. - **D** — controlled animal experiment in a related tissue. BPC-157 and TB-500 both hold a D: their results are in tendon, ligament, muscle and nerve, never in a disc. - **E** — cells in a dish, or a mechanism argued from a related pathway. - **F** — no experiment of any kind. Read the grade column and one thing jumps out. The compound with the strongest evidence is the one usually treated as the optional add-on, and the two compounds the stack is named after are the two graded D. If evidence quality drove what people bought, the ordering would be reversed. ## The nerve is the only link with randomised human evidence behind it ARA-290, generic name cibinetide, is an eleven-amino-acid piece of erythropoietin — the hormone that tells bone marrow to make red blood cells. It was built by cutting out the section of that hormone responsible for tissue repair while leaving out the section responsible for red cells. That split works because the two jobs run through two different receptors. Red cell production runs through the classical receptor. Tissue repair runs through a different pairing, which appears on tissue only after it has been damaged and is absent from healthy tissue. So the compound has, by design, almost nothing to bind to in an uninjured body, and it does not thicken the blood the way erythropoietin does. The pharmacology has one oddity worth understanding, because it looks like a contradiction. A 4 mg injection under the skin peaks at about 3 ng/mL in the blood and is gone in roughly twenty minutes. Yet it is dosed once a day and the effects last for days. The reason is that binding the receptor starts a repair programme inside the cell, and the programme keeps running long after the compound has cleared. Short life in the blood, durable effect in the tissue. [[embed:ara-290]] ## ARA-290's trials were real, and not one of them enrolled a back Six human studies exist. One hundred and thirty-two people have received active compound across all of them. Three of the six missed their main endpoint. Here is every one. | Study | Registration | People | Who was enrolled | Dose | Length | Result | |---|---|---|---|---|---|---| | Culver 2017, Phase 2b | NCT02039687 | 64, 16 per arm | Nerve fibre loss from sarcoidosis, with nerve pain | 1, 4 or 8 mg under the skin, daily | 28 days | Hit at one dose only. Corneal nerve fibre area above placebo: 109 µm² at 1 mg (not significant), 697 µm² at 4 mg (p = 0.012), 431 µm² at 8 mg (not significant). Pain in the moderate-to-severe group, p = 0.157, not significant | | Brines 2015 | NTR3858 | 49 enrolled, 48 analysed | Type 2 diabetes with painful nerve damage in the feet | 4 mg under the skin, daily, self-injected | 28 days, followed 56 | Hit. HbA1c fell 0.16% at day 28 against 0.01% for placebo, p = 0.002. Pain score improved significantly. Nerve fibre density rose 2.6 ± 1.0 fibres/mm² in the 18 people whose baseline was genuinely abnormal, p = 0.02 | | Dahan 2013 | Single centre, Leiden | 38 | Sarcoidosis with confirmed small nerve fibre loss | 4 mg under the skin, daily | 28 days | Split. Corneal nerve fibre density rose significantly. Skin nerve fibre density rose 0.38 ± 0.48 fibres/mm, 7.2% of baseline, not significant. Symptoms, temperature sensing and walking distance all improved | | Heij 2012 pilot | No registration number | 22, 12 active | Sarcoidosis with nerve symptoms | 2 mg into a vein, three times a week | 4 weeks | Hit. Symptom score fell 11.5 ± 3.04 against 2.9 ± 3.34 for placebo, p < 0.05. Pain inventory and fatigue improved equally in both arms, so no separation there | | Cerit 2015 | NCT02070783 | 36 healthy volunteers | Healthy adults, mood-processing model | 2 mg, single dose | One week | Missed. Some change in emotional processing, no effect on mood | | Diabetic macular oedema | NCT06626971 | — | Swelling at the back of the eye in diabetes | — | — | Terminated | [[embed:source:s1]] [[embed:source:s2]] Three things follow, and all three matter to somebody reading this with a leg that burns. **The positive results cluster in one disease.** Three of the four hits are in sarcoidosis, where the nerve damage is driven by the immune system attacking the small fibres. That is a different cause from a nerve root squeezed and chemically irritated by a disc. **The dose that worked is 4 mg a day and the dose above it did not work.** In the Phase 2b, 4 mg separated from placebo and 8 mg did not. A compound whose effect rises then falls as the dose climbs cannot be dosed by guesswork, and the doses people actually take — 250 to 1,000 mcg a day — sit four to sixteen times below the only dose that has ever worked. **Nobody has run it against a compressed nerve root.** Not in a person, not in an animal. The entire nerve argument for a disc is a read-across from a different disease with a different cause, and read-across is exactly the step that fails most often in drug development. [[embed:source:s3]] ## The chemical-irritation link is the weakest one, and it has been tested hard The strongest case for BPC-157 and TB-500 in a disc is usually made on inflammation rather than structure: the argument that they calm the TNF-alpha driven chemistry making the nerve root hurt. That target has been tested in humans, properly, with a far more potent tool than a peptide. Etanercept is a drug that blocks TNF-alpha directly. Put at the nerve root against epidural steroid in subacute lumbar nerve pain, it lost — steroid beat saline by 1.26 points on leg pain, which did not reach significance, and etanercept did worse than steroid on function by a margin that did. One other trial of 49 patients found separation only at the lowest of three doses, 0.5 mg, with the 2.5 mg and 12.5 mg arms not separating, at a loose significance threshold. [[embed:source:s24]] [[embed:source:s4]] So the most potent, most targeted available block of TNF-alpha at a nerve root produced a null in the best-controlled trial and an upside-down dose response in the one positive trial. Two peptides with weaker, broader, unmeasured effects on the same pathway are proposed to succeed where that failed. That is the ceiling on the inflammation argument, and it is low. [[embed:what-are-peptides-herniated-disc]] ## Two of the three have been tested together once, and the pair beat neither alone In July 2026 a Turkish orthopaedic group published the only experiment that has ever put BPC-157 and TB-500 in the same animals and compared the pair against each one alone. Biçer and colleagues, Joint Diseases and Related Surgery, PMID 42542926. Thirty-two rats. Achilles tendon cut across and surgically repaired. Four weeks of daily injection into the belly cavity, in four groups of eight: nothing, BPC-157 at 10 µg/kg/day, TB-500 at 60 µg/kg/day, or both. Outcomes were breaking strength on a testing machine plus two scored measures of tissue quality read blind under a microscope. What it found: TB-500 alone raised breaking strength against control (p < 0.05) and improved both tissue scores (p = 0.016 and p = 0.017), with the most ordered collagen fibres of any group. BPC-157 alone was numerically better than control without reaching significance. And the combination, in the authors' words, "did not confer additional benefits compared to either agent alone." Their own explanation is that the two probably feed into shared machinery further downstream, so pushing from two directions does not push harder. [[embed:source:s5]] That is the single most important negative result for anyone building a stack, and it deserves to be read straight rather than explained away. ## Four ways that result could be wrong for a disc Each of these names an experiment, not a caveat. **Wrong tissue.** A stitched rat Achilles has some blood supply. A disc has essentially none, and the whole argument for BPC-157 is about growing vessels where there are none. A combination could be redundant in a tissue that already gets blood and not redundant in one that gets none. The experiment: the same four-arm design in a disc breakdown model. **One dose of each.** Ten µg/kg of one and 60 µg/kg of the other, and nothing else tried. ARA-290's own human trials show why that matters — 4 mg worked and 8 mg did not, in the same trial. A single pair of doses tests one point, not the surface. The experiment: three dose levels of each, nine combination arms. **A ceiling in the measurement.** TB-500 alone already hit significance on strength and on both tissue scores. If a stitched tendon at four weeks heals about as well as that model permits, there is no headroom for a combination to show anything, and the null means the ruler ran out. The experiment: repeat with a harder injury — a bigger gap, a delayed repair, an older animal — so the control arm heals badly. **Four weeks.** Both dosing and measurement stopped at four weeks. Collagen keeps reorganising for months, and the ordered-fibre finding is precisely the kind of result that can diverge later. The experiment: the same design read at twelve and twenty-four weeks. ## All three together has never been tested in anything No study in any species, at any dose, by any route, has given BPC-157, TB-500 and ARA-290 together. There is no animal experiment, no case series, no registry entry. The three-compound version of this stack rests entirely on the argument that the three act on different things and therefore should not get in each other's way. That argument has one piece of evidence against it already, and the evidence is on this page: the only time two of the three were tested together, adding the second one bought nothing. [[embed:wolverine-stack]] ## One February 2026 registry entry could move the evidence base, and its companion declares itself fictional Two entries naming these compounds were filed on ClinicalTrials.gov in February 2026, both by the same sponsor, Hudson Biotech. A registry entry is a filing by the sponsor; nobody at the registry checks it, and neither entry has posted a result. | Trial | Compound | People | Design | What it measures | Started | |---|---|---|---|---|---| | NCT07437547 | BPC-157 | 120 planned | Phase 2, randomised, double-blind, placebo-controlled. Grade II hamstring strain confirmed on MRI. Under the skin, once daily for 14 days | Days to unrestricted return to sport at 8 weeks; change in injury volume on MRI at day 14, read by radiologists blind to the group | 2 February 2026 | | NCT07487363 | TB-500 | 80 planned | Phase 1/2, randomised, double-blind, placebo-controlled, stepped dose escalation, in adults with stable atherosclerotic heart disease | Side events at 12 weeks, serious events at 28 days, plus how the body absorbs and clears it | 5 February 2026 | [[embed:source:s20]] Take the second row first, because it decides how much weight the first can carry. The public summary of NCT07487363 opens: "This fictional study is an example of a ClinicalTrials.gov-style record." Its dose field says the levels "are not provided in this public example." It is a template, not a trial. The same sponsor filed eight entries of this shape between 2 and 15 February 2026 — covering BPC-157, TB-500, GHK-Cu, MOTS-c, melanotan II, tesamorelin, tirzepatide and retatrutide, one study site each. The first row is the one that would matter. NCT07437547 has an imaging endpoint read by people who do not know who got what, which would make it the first study capable of saying whether BPC-157 changes the size of a real injury in a real person. Its listed site is Peking University Shenzhen Hospital. It is a hamstring, not a disc, and 14 days, not twelve weeks, so it will not answer the question on this page. It would answer whether the compound does anything measurable in a human body at all, which is the question underneath it — and it answers nothing until it reports. Three separate orthopaedic and sports medicine reviews published in 2026 — in Sports Medicine, in the American Journal of Sports Medicine, and in the Journal of the American Academy of Orthopaedic Surgeons — audited this same literature independently and landed in the same place: real animal record, absent human record, unregulated products. [[embed:source:s21]] [[embed:source:s22]] ## The number any protocol has to beat is the disc's own recovery rate This is the number most vendor pages leave out and it changes every decision on this page. A 2024 meta-analysis pooled 31 studies and 2,233 people with a lumbar disc herniation treated without surgery. The overall rate at which the herniation shrank on its own was 70.39%. Broken out by type: 87.77% for a fragment that has broken free, 66.91% for an extrusion, 37.53% for a protrusion, 13.33% for a simple bulge. Counter to intuition, the bigger and more displaced the herniation, the more likely the body removes it. [[embed:source:s23]] That is the base rate. Seven in ten resolve with nothing done. Anybody who runs a twelve-week protocol during that window and improves has, on the numbers, a 70% chance of having improved anyway. One person cannot separate those two outcomes, and no amount of conviction about the result changes that. [[embed:herniated-disc]] ## Seven people with a back problem wrote down what happened Self-reports are counted here the same way they are counted anywhere on this site: the person had to state an outcome for themselves, commentary and dosing posts with no result attached were excluded, and negative reports are given the same space as positive ones. Filtering the self-report record to people describing a back, disc or sciatic problem specifically gives seven usable reports. | Outcome | Count | |---|---| | Said it helped | 4 | | Said nothing changed | 2 | | Said something got worse | 1 | | **Total** | **7** | **Helped — X, @MuroCrypto, 31 July 2026, anecdotal.** "My lowest disc in the lower back is dried out, almost no fluid left, classic herniated disc. Flared up hard in March, could barely sit or stand without pain. Went on for 3 months with zero improvement. In June I ran BPC-157 and TB-500 for about 6 weeks... After 3-4 weeks it already felt better." [[embed:source:s6]] **Helped — Reddit, u/kunukxathletix, r/Sciatica, 7 March 2026, anecdotal.** "I tried ever and eventually decided to try injectable BPC 157 and within a few weeks pain started to ease, well this could be random so I continued use after about 6-7 weeks sciatic pain was almost all the way gone." [[embed:source:s7]] **Helped — X, @drmarlonperalta, 4 June 2026, anecdotal.** "I've suffered for 10+ years with lower back pain from a herniated disc... A 6-week cycle removed this distraction permanently." [[embed:source:s8]] **Helped, with the writer's own warning attached — X, @AJA_Cortes, 26 May 2024, anecdotal.** "Decided to try to taking oral BPC157 at 2000mcg daily. Also got two deep tissue massages, and a chiro adjustment. 7 days later, pain free. Did the BPC157 help? Maybe, maybe not. Im always open to possibility of placebo." [[embed:source:s9]] **Nothing changed — Reddit, u/ImNotSchema, r/backpain, 19 August 2025, anecdotal, ran both compounds.** "I also experimented with TB500 and BPC-157 peptides, but saw no improvement. The one thing that actually helped was Prednisone." [[embed:source:s10]] **Nothing changed — Reddit, u/Dizzy-Breakfast-9405, r/backpain, 25 April 2024, anecdotal.** "I even tried peptides (BPC-157) for a month, no results." [[embed:source:s11]] **Worse — Reddit, u/Miserable_Fan1984, r/backpain, 16 September 2024, anecdotal, herniated disc, ran both compounds.** "I started taking bpc 157 and tb 500 and 500mcg a day to help with healing but I have started to feel worse and have pain going down my leg again." [[embed:source:s12]] Seven is too few to mean anything statistically, and four in seven reporting improvement is what a 70% spontaneous shrink rate would produce with no compound involved at all. What the seven do establish is that the negative and the worse outcomes exist, are specific, and are written by people who wanted the opposite result. The wider self-report set across all injuries — 40 reports, 21 helped, 15 nothing, 4 worse — is counted in full on the two-compound page. [[embed:wolverine-stack]] ## What people report on ARA-290, which is a much thinner record Four ARA-290 self-reports were found, and only one of them states an outcome. [[embed:source:s13]] The other three: one person two doses into a run for small fibre nerve damage with six to eight weeks left and no result yet, one post quoting the Phase 2b trial numbers rather than personal experience, and one skeptic asking the sharpest question in the whole set — whether repair signalling does anything while the nerve is still being squeezed. [[embed:source:s14]] That question has no published answer. Nobody has tested repair signalling against an ongoing mechanical squeeze. Not one report was found, on any platform, of a person running all three compounds together. The three-compound stack has no human record at all — not a trial, not a case, not a forum post. ## Reconstituting three vials, one arithmetic at a time All three ship as dry powder in a sealed glass vial. All three are mixed with bacteriostatic water — sterile water with 0.9% benzyl alcohol in it as a preservative, which is what makes it safe to put a needle into the same vial more than once. All three are measured on a U-100 insulin syringe, where 100 marks equal 1 mL, so one mark is 0.01 mL. Two lines of arithmetic cover all three: - Concentration in mcg per mL = total mcg in the vial ÷ mL of water added. - Mcg per mark = concentration ÷ 100. **BPC-157, 10 mg vial, 2 mL of water.** 10 mg = 10,000 mcg. 10,000 ÷ 2 = 5,000 mcg/mL. 5,000 ÷ 100 = 50 mcg per mark. A 500 mcg dose = 500 ÷ 50 = 10 marks = 0.10 mL. **TB-500, 10 mg vial, 2 mL of water.** Identical arithmetic: 50 mcg per mark. 500 mcg = 10 marks. 2.5 mg = 2,500 ÷ 50 = 50 marks = 0.50 mL. **ARA-290, 10 mg vial, 1.25 mL of water.** 10,000 ÷ 1.25 = 8,000 mcg/mL. 8,000 ÷ 100 = 80 mcg per mark. The 4 mg trial dose = 4,000 ÷ 80 = 50 marks = 0.50 mL, which is exactly the volume injected in the diabetes trial. Add 2 mL instead and you get 5,000 mcg/mL, 50 mcg per mark, and 4 mg becomes 80 marks. | Compound | Vial | Water | Concentration | Mcg per mark | 250 mcg | 500 mcg | 1 mg | 4 mg | |---|---|---|---|---|---|---|---|---| | BPC-157 | 10 mg | 2.0 mL | 5,000 mcg/mL | 50 | 5 marks | 10 marks | 20 marks | 80 marks | | BPC-157 | 20 mg | 4.0 mL | 5,000 mcg/mL | 50 | 5 marks | 10 marks | 20 marks | 80 marks | | TB-500 | 10 mg | 2.0 mL | 5,000 mcg/mL | 50 | 5 marks | 10 marks | 20 marks | 80 marks | | ARA-290 | 10 mg | 1.25 mL | 8,000 mcg/mL | 80 | 3.1 marks | 6.25 marks | 12.5 marks | 50 marks | | ARA-290 | 10 mg | 2.0 mL | 5,000 mcg/mL | 50 | 5 marks | 10 marks | 20 marks | 80 marks | Below about five marks the graduations on a U-100 barrel are too close together to read, which is why the dilute ARA-290 fill is the right one if the dose is under a milligram. Handling notes that apply to all three. Bring the vial to room temperature first. Run the water slowly down the inside wall rather than squirting it onto the powder. Swirl until clear, never shake — shaking tears peptide molecules apart at the air-water boundary and makes them clump, and clumping is the specific mechanism FDA named when it flagged the risk that the immune system reacts to these products. Once mixed, a vial keeps about four weeks in a fridge at 2–8 °C, which is the preservative's specification rather than a stability measurement on these peptides. Never freeze a mixed vial. ## A full day of all three, in marks and millilitres | Pattern | BPC-157 | TB-500 | ARA-290 | Total marks | Total volume | Injections | |---|---|---|---|---|---|---| | Reachable doses | 500 mcg = 10 marks | 500 mcg = 10 marks | 1 mg = 20 marks | 40 | 0.40 mL | 3 | | ARA at the dose that was actually trialled | 500 mcg = 10 marks | 500 mcg = 10 marks | 4 mg = 80 marks | 100 | 1.00 mL | 3 | | BPC daily, TB twice weekly, ARA at the trial dose | 500 mcg = 10 marks | 2.5 mg = 50 marks, twice weekly | 4 mg = 80 marks | 90 most days, 140 twice a week | 0.90–1.40 mL | 2, or 3 twice weekly | All figures assume 5,000 mcg/mL for BPC-157 and TB-500 and 5,000 mcg/mL for ARA-290. Do not mix any two of them in one syringe — different concentrations, different volumes, different schedules, and combining them makes every later adjustment a guess. Note the second row. Running ARA-290 at the only dose ever shown to work in a person means the third injection is four times the volume of the other two put together. ## Twelve weeks of all three, priced to the dollar Prices are from named research-chemical vendors, read on 4 August 2026. Nationwide Peptides publishes a range across vial sizes rather than a price per size, so the endpoints are what can be quoted exactly. - BPC-157: $42.00 smallest listed size (5 mg), $63.00 largest (20 mg). - TB-500: $38.00 smallest listed size (5 mg), $61.00 largest (10 mg). - ARA-290: $43.00 at Nationwide Peptides; Luxe Peptides lists 10 mg at $50.00 and 16 mg at $70.00. The arithmetic below uses $50 per 10 mg. [[embed:source:s15]] [[embed:source:s16]] Twelve weeks is 84 days. Every line shown: **BPC-157 at 500 mcg a day.** 84 × 500 mcg = 42,000 mcg = 42 mg. Buying 20 mg vials: 3 vials (60 mg) × $63 = **$189**. Per day: $189 ÷ 84 = **$2.25**. A 20 mg vial at 500 mcg a day is 40 doses, but a mixed vial only keeps about 28 days, so 12 doses per vial get thrown away — that waste is already in the price. **TB-500 at 500 mcg a day.** 42 mg. 5 × 10 mg vials × $61 = **$305**. Per day: **$3.63**. Each vial is 20 doses, which fits the four-week window with nothing wasted. **ARA-290 at 1 mg a day.** 84 mg. 9 × 10 mg vials × $50 = **$450**. Per day: **$5.36**. Each vial is 10 doses, well inside the window. **ARA-290 at the 4 mg trial dose.** 84 × 4 mg = 336 mg. 34 × 10 mg vials × $50 = **$1,700**. Per day: **$20.24**. Each vial lasts two and a half days. **Consumables.** Bacteriostatic water, insulin syringes, alcohol swabs: about $40 for a three-compound twelve-week run at retail. | What is run | Twelve-week materials | Per day | |---|---|---| | BPC-157 alone, 500 mcg/day | $189 + $40 = **$229** | $2.73 | | TB-500 alone, 500 mcg/day | $305 + $40 = **$345** | $4.11 | | ARA-290 alone, 1 mg/day | $450 + $40 = **$490** | $5.83 | | ARA-290 alone, at the 4 mg trial dose | $1,700 + $40 = **$1,740** | $20.71 | | All three, reachable doses | $189 + $305 + $450 + $40 = **$984** | $11.71 | | All three, ARA-290 at the trial dose | $189 + $305 + $1,700 + $40 = **$2,234** | $26.60 | The last two rows contain the honest problem with this stack. The compound holding the only randomised human evidence costs more than the other two combined at the dose that was tested, and costs about the same as them at a dose nobody has tested. Most people who buy all three resolve that by running ARA-290 at a quarter to a sixteenth of the trial dose, which means running the strongest-evidenced compound at a strength for which there is no evidence at all. None of these prices buys a verified product. There is no pharmacy channel for any of the three. A batch-specific purity test and a mass-spectrometry identity report from an independent lab is the only thing standing between a buyer and a vial of something else, and an eleven-amino-acid peptide with a ring-closed front end, which is what ARA-290 is, is not an easy molecule to synthesise correctly. ## Twelve weeks with a worn L5-S1 and a leg that burns One case, walked all the way through, with money, hours, measurements, decision points and failure conditions written down before anything starts. **Week 0 — what exists, and what gets measured.** L5-S1 disc dried out and lost height on MRI, a small protrusion touching the S1 nerve root, burning down the back of the left calf into the outer foot. Leg pain 7/10, back pain 4/10. No weakness, no bowel or bladder change, no numbness in the saddle area — those three would be an emergency and would end this plan immediately. MRI already done: $400–$1,800 cash, $250–$400 typical Medicare allowable, 1 hour. Five baseline measures written down, because a result nobody measured is a result nobody has: 1. Leg pain, 0–10, worst in the last 24 hours. 2. Oswestry Disability Index, a standard back questionnaire, scored out of 100. 3. Straight-leg-raise angle at which the leg pain starts, measured against a wall. 4. Nights woken by pain, per week. 5. Distance walked before the leg forces a stop. **Weeks 1–12 — the part with human trials behind it.** Load management and progressive exercise, twice weekly for six weeks then weekly. 18 visits at $75–$150 = **$1,350–$2,700**, about 18 clinic hours plus 20 hours of home work. This is the only line on the page supported by randomised human trials in this exact condition, and it also happens to be the biggest line in money and hours. Everything else is added on top of it, never instead. **Weeks 1–12 — the compounds, if they are run.** BPC-157 500 mcg a day, TB-500 500 mcg a day, ARA-290 1 mg a day, all under the skin of the abdomen, three separate injections. Materials **$984**. Time: about 6 minutes a day for three injections, so 8.4 hours over twelve weeks, plus roughly 35 minutes reconstituting seventeen vials. **Week 4 — first decision point.** Stopping rule set in advance: if nights woken has not fallen and the straight-leg-raise angle has not gained at least 10 degrees, ARA-290 stops. The reason it is ARA-290 that gets tested first is that it is the most expensive line and the one with the most specific promise — it either does something to nerve symptoms or it does not, and nerve symptoms are the fastest-moving measure on the list. Money saved by stopping there: **$300**. **Week 6 — second decision point.** If leg pain has not moved at all, the whole compound protocol stops and the money goes to the exercise programme, which continues either way. Money saved: about **$450**. **Week 8 — the escalation gate.** If leg pain is still 6/10 or above and disability is still above 40, this is where an epidural steroid injection sits in standard practice: $800–$5,000 cash, $161 Medicare allowable, 3 hours including travel and recovery. The pooled evidence gives it about 6 points on a 0–100 leg pain scale short term, which is below the 10-to-30-point range most people would call a meaningful change. **Week 12 — the state at the end.** Running total: $1,350–$2,700 physical therapy, $984 materials, $400–$1,800 MRI, $0–$5,000 if an injection was used. Total **$2,734 to $10,484**. Patient time: roughly 47 hours. Base-rate expectation, from the 2,233-patient pooled data, is substantial improvement in leg pain for most people over twelve weeks with no compounds at all. **What would count as failure, written before the start.** - No movement on nights woken or straight-leg-raise angle at week 4. - No movement on leg pain at week 6. - Any new problem: swelling, worse pain in an untreated area, any change in vision. - New weakness, new numbness in the saddle area, or any bowel or bladder change at any point — stop everything and get seen the same day. - Relief that arrives inside a week and disappears within two weeks of stopping. That pattern points at irritation settling rather than tissue rebuilt, and it means the compounds bought a symptom holiday, not a repair. **The week 12 decision.** Disabling leg pain past twelve weeks, with imaging that matches the symptoms, is where surgery stops being premature. Microdiscectomy runs $15,000–$50,000 list, measured at $14,137 above non-surgical care over two years in trial data, and it buys faster relief rather than a better one-year outcome — the recovery rate at a year is the same either way. ## Where United States law puts all three, which is not the same place None of the three is an approved medicine in the United States. None is banned outright. But their positions differ, and the difference is worth knowing before buying. **BPC-157 and TB-500** both appear on FDA's public list of bulk drug substances "nominated but withdrawn" — put forward for use in compounded medicines, placed in the agency's category 2 for possible significant safety risks, then pulled by whoever nominated them. FDA's stated concerns are, in its own words, that products containing BPC-157 "may pose risk for immunogenicity for certain routes of administration", and that for the thymosin beta-4 fragment "FDA has not identified any human exposure data" and "lacks important information regarding any safety issues raised by this drug, including whether it would cause harm if administered to humans." **ARA-290 appears nowhere on those lists.** It was never nominated for compounding at all. That is not a cleaner status — it is a thinner one. It means no regulator has published a safety assessment of it as a compounding ingredient, favourable or otherwise. It did receive orphan drug designation in both the United States and Europe, and then its developer stopped, so there is no late-stage programme and no pharmaceutical supply of it anywhere. What follows in plain terms: - No pharmacy can lawfully compound any of the three. None is on the 503A list traditional compounding pharmacies work from, nor the 503B list outsourcing facilities work from. - On 23–24 July 2026 FDA's Pharmacy Compounding Advisory Committee voted 8–6, one abstention, in favour of allowing BPC-157 and TB-500 to be compounded, against FDA's own written recommendation. That vote is advice. It binds nothing, approves nothing, and the rulemaking it starts realistically runs eight to twelve months. - "Research use only" printed on a vial is a shipping label. It is not a legal category and it makes nothing safe or lawful to inject. [[embed:source:s17]] [[embed:source:s18]] ## One of the three ends a tested athlete's season Anyone competing under anti-doping rules — collegiate, professional, masters, a national federation, an Olympic pathway — and anyone serving in the United States military needs this before anything else on the page. - **TB-500 is named on the WADA 2026 Prohibited List**, under S2.3, growth factors: "Thymosin-ß4 and its derivatives e.g. TB-500." Prohibited at all times, in and out of competition, in the harsher non-specified tier. The catch-all in that same clause covers substances affecting "muscle, tendon or ligament protein synthesis/degradation, vascularisation, energy utilization, regenerative capacity" — the exact reason to take it is written into the ban. - **BPC-157 is named** under S0, non-approved substances, also prohibited at all times. - **ARA-290 is not named**, but S0 covers any substance with no current approval by any government health authority for human use, and ARA-290 has none. Treat it as covered. - Strict liability applies. Intent does not matter and neither does who recommended it. The Canadian Centre for Ethics in Sport imposed a four-year ban on an athlete for BPC-157 and TB-500. - A sanction does not require a positive test. An admission, a possession finding, or a purchase record is enough. - The Department of Defense lists BPC-157 on its prohibited supplement ingredients list and states that it is not a dietary ingredient, it is an unapproved drug. [[embed:source:s19]] There is no off-season window. Off-season use is a violation. ## What would prove each link wrong The value of a stack argued as separate links is that each link can be broken separately. Here is what would break each one, with the current state of the evidence beside it. | Link | Current state | The result that would break it | |---|---|---| | Blood supply reaching the disc, BPC-157 | Grade D. Repeated positive results in tendon, ligament, muscle, nerve and spinal cord in rats, mostly from one research group. Nothing in a disc, ever | A controlled animal study in a disc, counting vessels and measuring disc height, showing no difference against control | | Repair cells crawling in, TB-500 | Grade D. One controlled rat tendon study with 8 per arm. The ligament and skin results used the full 43-amino-acid protein, not the 7-amino-acid fragment that is sold | The rat tendon study repeated at a larger size with no strength difference; or a direct comparison of the fragment against the full protein showing the fragment does nothing | | Nerve fibres regrowing, ARA-290 | Grade B. Randomised human trials with a measured structural endpoint, in a different disease, never in a compressed root | A randomised trial in a compressed nerve root showing no separation from placebo | | Chemical irritation calmed, BPC-157 and TB-500 | Grade E, and already damaged. Direct TNF-alpha blockade at the nerve root produced a null against steroid in the best-controlled trial | Nothing further needed — the burden here sits with anyone claiming the peptides beat what etanercept could not | | The three acting on different things | Grade F. Never tested. The only test of two of them together found the pair beat neither alone | A three-arm animal study — each compound alone, all three together — showing the three-way combination matches the best single agent | | Anything beating the disc's own recovery | Grade F. 70.39% of herniations shrink on their own | Any protocol that has not been measured against a control group in this condition cannot claim to beat 70% | Five links. One at grade B, two at D, one at E, two at F. Not one at grade A, because no randomised trial of any of these compounds has ever enrolled a person with a disc problem. That is the honest state of it. The mechanism argument is coherent, the three compounds genuinely act on different things, and the amount of measurement behind that coherence ranges from real human trials on one link to literally nothing on another. [[embed:bpc-157]] [[embed:tb-500]] [[embed:ara-290]] [[embed:what-are-peptides-herniated-disc]] [[embed:wolverine-stack]] ## Sources 1. Culver DA et al. Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain. Phase 2b, NCT02039687. PMID 28475703 — https://pubmed.ncbi.nlm.nih.gov/28475703/ 2. Brines M et al. ARA 290 in type 2 diabetes with painful neuropathy — randomised double-blind placebo-controlled trial, NTR3858, full text with pharmacokinetics and adverse events — https://pmc.ncbi.nlm.nih.gov/articles/PMC4365069/ 3. ClinicalTrials.gov NCT02039687 — Study of Efficacy of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With Sarcoidosis. Completed — https://clinicaltrials.gov/study/NCT02039687 4. Cohen SP et al. Epidural steroids, etanercept, or saline in subacute sciatica: a multicenter, randomized trial. Ann Intern Med 2012. PMID 22508732 — https://pubmed.ncbi.nlm.nih.gov/22508732/ 5. Biçer O, Adanir O, Güleryüz Y, Balci EC. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Jt Dis Relat Surg, 23 July 2026. PMID 42542926 — https://pubmed.ncbi.nlm.nih.gov/42542926/ 6. X — @MuroCrypto, 31 July 2026 — anecdotal, positive, herniated lumbar disc, ran both compounds — https://x.com/MuroCrypto/status/2083184469956059529 7. Reddit r/Sciatica — u/kunukxathletix, 7 March 2026 — anecdotal, positive, sciatic pain — https://www.reddit.com/r/Sciatica/comments/1rnicr5/pinched_sciatic_nerve/ 8. X — @drmarlonperalta, 4 June 2026 — anecdotal, positive, ten years of low back pain from a herniated disc — https://x.com/drmarlonperalta/status/2062565899714925044 9. X — @AJA_Cortes, 26 May 2024 — anecdotal, positive, L5-S1 flare, writer flags placebo himself — https://x.com/AJA_Cortes/status/1794522474702336108 10. Reddit r/backpain — u/ImNotSchema, 19 August 2025 — anecdotal, no effect, ran both compounds — https://www.reddit.com/r/backpain/comments/1mu96us/hlab27_sacroiliitis_on_mri_vs_disc_obliteration/ 11. Reddit r/backpain — u/Dizzy-Breakfast-9405, 25 April 2024 — anecdotal, no effect after a month — https://www.reddit.com/r/backpain/comments/1ccysh4/chronic_onesided_thoracic_pain/ 12. Reddit r/backpain — u/Miserable_Fan1984, 16 September 2024 — anecdotal, got worse, herniated disc, ran both compounds — https://www.reddit.com/r/backpain/comments/1fi50ar/bpc_157_and_tb_500_for_herniated_disc/ 13. X — @NewsDeskOne, 17 July 2026 — anecdotal, positive, ARA-290 for nerve symptoms in the feet — https://x.com/NewsDeskOne/status/2077929820760019113 14. X — @vedichi_, 16 July 2026 — anecdotal, skeptical, names the read-across problem directly — https://x.com/vedichi_/status/2077787145238913472 15. Nationwide Peptides — ARA-290 (cibinetide), BPC-157 and TB-500 research-chemical listings, prices read 4 August 2026 — https://www.nationwidepeptides.com/products/ara-290-cibinetide-peptide/ 16. Luxe Peptides — ARA-290 peptide listing, prices read 4 August 2026 — https://luxepeptides.is/ara-290/ 17. FDA — Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks, current as of 22 April 2026 — https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks 18. FDA — 23-24 July 2026 meeting of the Pharmacy Compounding Advisory Committee — https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026 19. World Anti-Doping Code International Standard — Prohibited List 2026, effective 1 January 2026 — https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf 20. NCT07437547 — A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Pentadecapeptide BPC 157 for Accelerated Repair of Acute Grade II Hamstring Strain Confirmed by MRI. Hudson Biotech. Recruiting, started 2 February 2026 — https://clinicaltrials.gov/study/NCT07437547 21. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med, 12 April 2026. PMID 41966639 — https://pubmed.ncbi.nlm.nih.gov/41966639/ 22. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. J Am Acad Orthop Surg Glob Res Rev, 1 January 2026. PMID 41490200 — https://pubmed.ncbi.nlm.nih.gov/41490200/ 23. Incidence of Spontaneous Resorption of Lumbar Disc Herniation: A Meta-analysis. Clin Spine Surg, 2024. PMID 37559207 — https://pubmed.ncbi.nlm.nih.gov/37559207/ 24. Randomized, double-blind, placebo-controlled trial of transforaminal epidural etanercept for symptomatic lumbar disc herniation. PMID 24165696 — https://pubmed.ncbi.nlm.nih.gov/24165696/ --- # The Wolverine stack: BPC-157 and TB-500, the evidence, the dosing arithmetic and the eight-week cost slug: wolverine-stack · https://miscsubjects.com/a/wolverine-stack · category: peptides · tags: peptide, bpc-157, tb-500, stack, tendon, wolverine · updated 2026-08-04T22:08:38.210Z The Wolverine stack is two compounds taken at the same time: BPC-157 and TB-500. People run it after a tendon tear, a bad shoulder, a knee that will not settle, a disc that has been hurting for months. The reason they are run together is not that one is stronger. It is that each one is proposed to fix a different step of the same repair job, so the argument goes that they should not overlap. The evidence state, up front. No controlled study has ever given both compounds to a person, in any condition, so the number of people who have taken the pair under measurement is nought. Separately the two are not equal. BPC-157 has five published human studies covering about 130 people, and not one of them is a finished controlled trial in a torn or worn tissue. The seven-amino-acid fragment sold as TB-500 has no human study at all and no established human dose. Two entries appeared on ClinicalTrials.gov in February 2026, filed by the same sponsor, Hudson Biotech: NCT07437547, a 120-person randomised, double-blind, placebo-controlled hamstring trial marked recruiting, and NCT07487363, which names TB-500 and whose own public summary states that it is a fictional example of a registry record. Neither has reported anything, and a registry filing is not a result. The animal record behind the pairing is rats, mice and rabbits — roughly 150 animal papers for BPC-157, a much smaller tendon and wound literature for the fragment — and the one experiment that ever put both compounds into the same rats found the combination beat neither compound on its own. What has never been measured in a person: the pair, at any dose, in any tissue, for any length of time. One disclosure, because it should change how you read the rest. The operator of this site has a commercial interest in compounds described here. That is a reason to weigh what is on this page against the sources it cites rather than against its tone, and every claim below carries the source that supports it for exactly that reason. This page sets out what each step is, how good the evidence is for each, what happened the one time somebody put both compounds into the same animals, what a run costs to the dollar, and what forty people who tried it wrote down afterwards. ## Two compounds aimed at two different steps of the same repair Damaged tendon, ligament and disc all repair in the same order. Blood has to reach the damaged spot. Repair cells have to crawl in from the surrounding tissue. Those cells have to lay down new collagen in ordered fibres rather than a random scar. Each step gates the next. BPC-157 is proposed to act on the first step. In animals it grows new blood vessels into damaged tissue, mostly by switching on a growth signal called VEGF and the nitric-oxide system that widens vessels. TB-500 is proposed to act on the second. It is a seven-amino-acid piece of a natural protein, thymosin beta-4, and the piece it copies is the part that grabs actin — the protein filament a cell builds and dismantles to change shape and crawl. Bind actin, and the cell's crawling machinery is freed up. A cell that cannot rebuild its own internal skeleton cannot move into a wound at all. That is the whole logic of the pairing. One opens the supply line, the other moves the workforce down it. Nothing in the pairing addresses a torn fibre mechanically, and nothing in it dissolves a bulged disc. [[embed:bpc-157]] [[embed:tb-500]] ## The bottleneck in tendon, ligament and disc is blood, and both compounds are aimed at it A muscle bruise heals in weeks. A tendon takes months. A spinal disc, in an adult, barely heals at all. The difference is blood supply. Muscle is dense with vessels. Tendon has few. The centre of an adult disc has none — nutrients cross in by seeping through the cartilage end plates, which themselves stiffen and calcify with age. That single fact is why both compounds are attractive on paper for these tissues and why neither has been shown to work in them. A drug aimed at growing vessels into a structure that has almost no vessels is aimed at the real rate-limiting step. It is also aimed at the hardest possible target, and the harder the target, the more the argument needs measurements rather than mechanism. ## What each one is proposed to build back, and what would prove it wrong | Compound | What it is proposed to do, in plain words | Strongest evidence behind that | What it adds that the other does not | What would prove it wrong | |---|---|---|---|---| | BPC-157 | Grow new blood vessels into damaged tissue and keep the repair cells there alive, so the site gets oxygen and raw material | Rat Achilles tendon torn off the bone and reattached came back mechanically stronger; cut ligament, crushed muscle and severed muscle-tendon join all healed faster than controls | The supply line. TB-500 does not act on the vessel-growth signal | A controlled animal study measuring blood vessel counts at the injury site showing no difference against control, or a human trial in tendon pain showing no separation from placebo | | TB-500 | Free up the internal scaffolding cells use to crawl, so repair cells reach the wound and lay ordered fibres rather than scar | Rat Achilles repair, 8 animals per arm, four weeks: higher load to failure than control (p < 0.05), better tissue score (p = 0.016), most ordered collagen of any arm under stain | The workforce. BPC-157 does not bind actin | A study measuring cell arrival at the wound showing no increase, or the same tendon model repeated at a larger size with no strength difference | | The pair together | Both steps at once, on the theory that a supply line without workers and workers without a supply line each stall | One study, in rats, found the combination did not beat either compound alone | Nothing that has been measured | Already partly answered — see the section below | The evidence grade is the same for both compounds and it is worth naming plainly: controlled animal experiments in the target tissue, no controlled human experiment in any tissue that hurts. ## The strongest single-compound results, best first | Rank | Finding | Species and model | Numbers | What it establishes | |---|---|---|---|---| | 1 | TB-500 raised maximum load to failure in a repaired Achilles tendon | Rat, tendon cut across and stitched, four weeks | 32 rats, 8 per arm, 60 µg/kg/day into the belly cavity, p < 0.05 | The only controlled measurement of mechanical strength for either compound in a repaired tendon | | 2 | BPC-157 healed a tendon torn off the bone | Rat, Achilles detached from the heel bone | Faster reattachment and greater strength than control | The structural claim in the tissue people buy it for | | 3 | BPC-157 sped recovery of a cut sciatic nerve | Rat, nerve cut and repaired | Faster return of function than control | The closest thing to a nerve result either compound has | | 4 | BPC-157 improved recovery after spinal cord injury | Rat, PMID 31266512 | Better function than control, sustained | Shows the compound reaches and acts on nervous tissue given by mouth or by injection away from the site | | 5 | Full-length thymosin beta-4 healed a cut knee ligament | Rat, ligament cut, 1 µg placed in the gap in fibrin glue | Uniform fibre bundles, significantly greater mechanical strength | The ligament result — but with the full 43-amino-acid protein, placed in the wound, not the 7-amino-acid fragment injected into fat | | 6 | Thymosin beta-4 closed skin wounds faster | Rat, full-thickness wound | Surface regrown 42% faster at four days, 61% at seven; more collagen, more vessels | The original result the whole thymosin beta-4 literature rests on | Rows 5 and 6 carry a caveat that changes how they read. They used full-length thymosin beta-4, a 43-amino-acid protein. What is sold as TB-500 is a 7-amino-acid piece of it, residues 17 to 23, with the front end capped. The two are not the same molecule, and FDA wrote that distinction down in July 2026. Reading a full-length result onto a fragment vial is the single most common error in this area. Three separate orthopaedic and sports medicine reviews published in 2026 — in Sports Medicine, in the American Journal of Sports Medicine, and in the Journal of the American Academy of Orthopaedic Surgeons — went through this same literature independently and reached the same place: the animal record is real, the human record is not there, and the products on sale are unregulated. [[embed:source:s34]] [[embed:source:s35]] ## Somebody finally put both in the same rats, and the pair beat neither one alone In July 2026 a Turkish orthopaedic group published the only experiment that has ever tested BPC-157 and TB-500 together against each one alone. Biçer and colleagues, in Joint Diseases and Related Surgery, PMID 42542926. The design, in full: 32 rats, Achilles tendon cut across and surgically repaired, then four weeks of daily injection into the belly cavity, split into four groups of eight — nothing, BPC-157 at 10 µg/kg/day, TB-500 at 60 µg/kg/day, or both together. Outcomes were maximum load to failure on a testing machine, plus two scored measures of tissue quality read under a microscope by people blinded to the group. The results: - TB-500 alone raised maximum load to failure against control, p < 0.05. - TB-500 alone improved the Bonar tissue score, p = 0.016, and the Movin score, p = 0.017. - Under a collagen stain, the TB-500 group had the most ordered type I collagen fibres. - BPC-157 alone came out numerically better than control and did not reach significance on total scores. - The combination, in the authors' own words, "did not confer additional benefits compared to either agent alone." That is the sentence the stack has to survive. Two compounds sold as a pair, tested as a pair for the first time, and the pair was no better than the better of the two. The authors' reading is that the two probably converge on shared downstream machinery — that once the repair programme is running, pushing it from two directions does not push it further. [[embed:source:s1]] ## Four reasons that one experiment does not close the question Each of these is a real experiment somebody could run, not a hedge. **One tissue.** The test was a surgically repaired Achilles tendon in a rat. Tendon has some blood supply. The place the stack is most often aimed at — a spinal disc — has almost none, and the argument for BPC-157 is specifically about growing vessels where there are none. The measurement that would answer this: run the same four-arm design in a disc model, or in a tissue with a poorer blood supply than tendon. **One dose level each.** BPC-157 got 10 µg/kg/day, TB-500 got 60 µg/kg/day, and nothing else was tried. If either compound's effect rises and then falls as the dose goes up — which is normal for signalling peptides and which the ARA-290 human trials actually showed, where 4 mg worked and 8 mg did not — then a single dose pair tests one point on a surface, not the surface. The measurement: a dose grid, three levels of each compound, nine combination arms. **A possible ceiling.** TB-500 alone already reached significance on strength and on both tissue scores. If a stitched rat tendon at four weeks heals about as well as that model allows, then a combination has no room left to show a difference, and a null result means the ruler ran out, not that the second compound is inert. The measurement: repeat with a harder injury — a larger gap, a delayed repair, or an older animal — so the control arm heals badly and there is space above it. **Four weeks.** Dosing and measurement both stopped at four weeks. Collagen in a healing tendon keeps remodelling for months, and the ordered-fibre finding is exactly the sort of thing that could diverge later. The measurement: the same design read at twelve and twenty-four weeks. None of those four is an argument that the combination works. They are the reasons the single null result does not settle it, and each one names the study that would. ## The experiment that would settle it A single trial would answer more than everything above. Take a tendon or ligament injury model with a poor blood supply and a control arm that heals badly. Run four arms at three dose levels each — nothing, BPC-157, TB-500, both — with 15 to 20 animals per arm rather than 8, dosed under the skin rather than into the belly cavity, because under the skin is how humans take it. Measure load to failure, blood vessel counts at the wound, and ordered collagen, at four weeks and at sixteen. Pre-register the dose grid. That study costs a fraction of one human trial and nobody has run it. Nothing has ever tested three of these compounds together, in any species, at any dose. Adding ARA-290 to this pair for nerve pain is set out separately, and the three-compound combination has zero experimental record of any kind. [[embed:wolverine-stack-ara-290]] ## No person has ever been given this pair in a controlled study Here is that fact as one row, with what does exist beside it. | Question | Answer | Basis | |---|---|---| | Controlled human trial of BPC-157 and TB-500 together | None, in any condition | Registry and literature searches return nothing | | Controlled human trial of TB-500 alone by injection | None, by any route | FDA's July 2026 review states it has found no human exposure data for products containing the fragment | | Controlled human trial of BPC-157 | Five studies exist; the largest musculoskeletal one is a telephone survey | Published record | | Human trials of full-length thymosin beta-4 | Yes — eye drops for dry eye and for corneal damage, topical gel for pressure sores | These are surface applications of a different molecule | | Human dose that has ever been established for either | None | No dose-finding study exists for either compound in a person | [[embed:source:s3]] ## Two registry entries were filed in February 2026, and one of them says it is a made-up example That last table has a date on it. As of 4 August 2026 ClinicalTrials.gov holds two entries naming these compounds. Both were filed by the same sponsor, Hudson Biotech, both give a start date in the first week of February 2026, and both are marked recruiting. Read that for what it is. A registry entry is a filing by the sponsor. Nobody at the registry checks it, and neither entry has posted a result. | Trial | Compound | People | Design | What it measures | When | |---|---|---|---|---|---| | NCT07437547 | BPC-157 | 120 planned | Phase 2, randomised, double-blind, placebo-controlled. Grade II hamstring strain confirmed on MRI. Injection under the skin, once daily for 14 days, given by study staff | Days until return to unrestricted sport, at 8 weeks; and change in injury volume on MRI at day 14, read by radiologists who do not know the group | Started 2 February 2026 | | NCT07487363 | TB-500 | 80 planned | Phase 1/2, randomised, double-blind, placebo-controlled, stepped dose escalation. Adults with stable atherosclerotic heart disease | Side events at 12 weeks, serious events at 28 days, plus how the body absorbs and clears it | Started 5 February 2026 | [[embed:source:s2]] Now read the second row against its own record. The public summary of NCT07487363 opens: "This fictional study is an example of a ClinicalTrials.gov-style record." Its dose field says the levels "are not provided in this public example." That entry is a template, not a trial, and any page citing it as proof that TB-500 is being tested in people is citing a placeholder. The same sponsor filed eight entries of this shape between 2 and 15 February 2026 — covering BPC-157, TB-500, GHK-Cu, MOTS-c, melanotan II, tesamorelin, tirzepatide and retatrutide, one study site each — and that is the company the first row keeps. The first row is the one that would matter. NCT07437547 has an imaging endpoint read by people who do not know who got what, which would make it the first study capable of saying whether BPC-157 changes the size of a real injury in a real person. Its listed site is Peking University Shenzhen Hospital. Neither entry tests the pair. Neither enrols anyone with a back problem. And a filing is not a finding: until NCT07437547 posts results, the number of randomised human results for either compound in a torn tissue stays at zero. ## Forty people wrote down what happened to them, and here is the tally Self-reports are not evidence of whether a compound works. They are evidence of what happens to people who take it, which is a different and still useful thing — it is where side effects, dose ranges and failure rates show up first, years before anybody runs a trial. Forty reports were counted. The rule for counting: the person had to state an outcome for themselves. Commentary about the compounds, dosing instructions with no result attached, and posts written mid-run before any outcome were excluded — sixteen entries were dropped on that rule. | Outcome | Count | Share | |---|---|---| | Said it helped | 21 | 52.5% | | Said nothing changed | 15 | 37.5% | | Said something got worse | 4 | 10% | | **Total counted** | **40** | | Every one of these is anecdotal. None was blinded, none had a control, and people who get a result post more readily than people who do not, so the true no-effect share is almost certainly higher than 37.5%. ### The twenty-one who said it helped [[embed:source:s4]] [[embed:source:s5]] [[embed:source:s6]] [[embed:source:s7]] [[embed:source:s8]] [[embed:source:s9]] [[embed:source:s10]] [[embed:source:s11]] [[embed:source:s12]] [[embed:source:s13]] [[embed:source:s14]] That last one is worth its own line. Pain that vanishes in days and returns within days of stopping is the signature of something calming irritation, not of something rebuilding a tendon. Rebuilt tissue does not un-rebuild in a week. Several of the fast-relief reports fit that shape better than they fit a repair story. The remaining ten in this group: u/DifficultReach2720 (foot, "basically fully healed" at three months), u/NoInvestigator7249 (elbow, range of motion back to 100%), u/frequentflyernine11 (wrist, close to previous strength after seven vials, still minor pain), u/sdBiotch ("not a miracle by any means but I can improve mobility"), u/SanketJ1986 (pain down in the treated arm, no change in the other), u/Quacka-moo ("It has helped a bit but I expected more"), @drmarlonperalta (ten years of low back pain from a herniated disc, "a 6-week cycle removed this distraction permanently"), @AJA_Cortes (L5-S1 flare, oral BPC-157 at 2,000 mcg a day, pain free in seven days, and his own comment was "maybe, maybe not — I'm always open to possibility of placebo"), @Breedlove22 (ran both, credited the pair), and @mindpumpsal. [[embed:source:s15]] [[embed:source:s16]] ### The fifteen who said nothing changed [[embed:source:s17]] [[embed:source:s18]] [[embed:source:s19]] [[embed:source:s20]] [[embed:source:s21]] [[embed:source:s22]] [[embed:source:s23]] [[embed:source:s24]] [[embed:source:s25]] The other six: u/Dizzy-Breakfast-9405 (a month, thoracic pain, no results), u/kayfab (capsules, ligament, nothing), u/Acrobatic-Car3352 (nine days into a blend, Achilles, no changes), u/forsaken3400 (day 5, shoulder, nothing beyond possibly better sleep), u/mite189 (the tear did not heal faster; recovery came with prescribed isometric work), u/mudra311 (elbow, "I felt better before the BPC as well"). ### The four who got a new problem [[embed:source:s26]] [[embed:source:s27]] [[embed:source:s28]] [[embed:source:s29]] Two of those four describe swelling or fluid at or near the treated site, and both compounds are proposed to grow blood vessels, which is a mechanism that would produce exactly that. The blurred vision report has no mechanism attached to it and no follow-up. ### What the tally can and cannot decide It cannot decide whether the compounds work. Half a sample reporting improvement in a condition where most soft-tissue injuries improve on their own over the same weeks is what a completely inert substance would also produce. It can decide four things. First, roughly one person in ten reports a new problem, and that number belongs in any decision. Second, the doses in real use cluster at 250 to 500 mcg a day for BPC-157, which is well below the milligram doses in every human study of BPC-157 that has been published. Third, the fast-relief-then-relapse pattern is common enough to suggest that much of what people feel is irritation settling rather than tissue rebuilding. Fourth, the failures are specific and repeated — several people ran it three separate times with nothing to show. ## Twelve of the forty ran both compounds, not one The tally above mixes people who took BPC-157 alone with people who ran the pair. Splitting out only those who explicitly ran both: | Outcome | Count | |---|---| | Helped | 6 | | Nothing changed | 4 | | Something got worse | 2 | | **Total** | **12** | Six helped out of twelve, against twenty-one out of forty in the whole set. Twelve people is far too small to compare against anything, and a 50% versus 52.5% gap means nothing at that size. What the split does show is that no signal jumps out in favour of running both, which is the same direction the rat study pointed. ## Turning a vial of powder into marks on a syringe Both compounds ship as a dry white powder in a sealed glass vial, usually 5, 10 or 20 mg. You add bacteriostatic water — sterile water with 0.9% benzyl alcohol in it as a preservative, which is what makes it safe to put a needle into the same vial repeatedly. Plain sterile water works chemically but has no preservative, so it is a one-entry proposition. The dosing tool is a U-100 insulin syringe. U-100 means 100 marks per millilitre, so one mark is 0.01 mL. Two lines of arithmetic give you everything: - Concentration in mcg per mL = total mcg in the vial ÷ mL of water added. - Mcg per mark = concentration ÷ 100. Worked all the way through, for a 10 mg vial with 2 mL of water: 1. 10 mg = 10,000 mcg. 2. 10,000 mcg ÷ 2 mL = 5,000 mcg per mL. 3. 5,000 ÷ 100 = 50 mcg per mark. 4. A 500 mcg dose = 500 ÷ 50 = 10 marks = 0.10 mL. | Vial | Water added | Concentration | Mcg per mark | 250 mcg | 500 mcg | 1 mg | 2.5 mg | Doses per vial at 500 mcg | |---|---|---|---|---|---|---|---|---| | 5 mg | 1.0 mL | 5,000 mcg/mL | 50 | 5 marks | 10 marks | 20 marks | 50 marks | 10 | | 5 mg | 2.0 mL | 2,500 mcg/mL | 25 | 10 marks | 20 marks | 40 marks | 100 marks | 10 | | 10 mg | 2.0 mL | 5,000 mcg/mL | 50 | 5 marks | 10 marks | 20 marks | 50 marks | 20 | | 10 mg | 3.0 mL | 3,333 mcg/mL | 33.3 | 7.5 marks | 15 marks | 30 marks | 75 marks | 20 | | 20 mg | 4.0 mL | 5,000 mcg/mL | 50 | 5 marks | 10 marks | 20 marks | 50 marks | 40 | Adding more water does not change how much compound is in the vial. It changes only how many marks carry a dose. Below about five marks the graduations on a U-100 barrel are too close together to read reliably, which is the practical argument for the more dilute fills when the dose is small. Handling that ruins the peptide is easy to do by accident. Bring the vial to room temperature first. Run the water slowly down the inside wall rather than squirting it onto the powder. Swirl until clear, never shake — shaking a peptide solution tears the molecules apart at the air-water boundary and makes them clump, and clumping is the exact mechanism FDA named when it raised the risk that the immune system reacts to these products. Once water is in, a vial keeps about four weeks in a fridge at 2–8 °C. That is the preservative's specification, not a stability measurement on these peptides — nobody has run one. Do not freeze a reconstituted vial; freezing and thawing makes short peptides clump. ## A full day of both compounds, in marks and millilitres Two common daily patterns, both at 5,000 mcg/mL: | Pattern | BPC-157 | TB-500 | Total volume | Injections per day | |---|---|---|---|---| | Both daily, low | 500 mcg = 10 marks = 0.10 mL | 500 mcg = 10 marks = 0.10 mL | 0.20 mL | 2 | | BPC daily, TB twice weekly | 500 mcg = 10 marks = 0.10 mL | 2.5 mg = 50 marks = 0.50 mL, Monday and Thursday | 0.10 mL most days, 0.60 mL twice a week | 1, or 2 twice a week | Do not mix the two in one syringe. They have different concentrations, different volumes and different schedules, and combining them makes every future dose adjustment guesswork. Where the needle goes was never resolved by the animal work, because the animals were dosed into the belly cavity or by drinking water, almost never at a site chosen to be near an injury. Several of the strongest structural results in rats — cut ligament, muscle torn off bone, spinal cord — came from animals drinking the compound in water and still repairing a specific distant injury. There is no head-to-head study showing an injection near the injury beats an injection into abdominal fat. ## Eight weeks of materials, priced with the arithmetic shown Prices below are from one named research-chemical vendor, Nationwide Peptides, read on 4 August 2026. They publish a range across vial sizes rather than a per-size price, so the two endpoints are what can be quoted exactly. - BPC-157: $42.00 for the smallest listed size (5 mg), $63.00 for the largest (20 mg). - TB-500: $38.00 for the smallest listed size (5 mg), $61.00 for the largest (10 mg). [[embed:source:s30]] Eight weeks is 56 days. The arithmetic: **BPC-157 at 500 mcg a day.** 56 days × 500 mcg = 28,000 mcg = 28 mg. - Buying 5 mg vials: 6 vials (30 mg) × $42 = **$252**. Cost per day = $252 ÷ 56 = **$4.50**. - Buying 20 mg vials: 2 vials (40 mg) × $63 = **$126**. Cost per day = $126 ÷ 56 = **$2.25**. Twelve milligrams get discarded, because a 20 mg vial at 500 mcg a day is 40 doses and a reconstituted vial only lasts about 28 days. Even throwing that away, the big vial is half the price of the small ones. **TB-500 at 500 mcg a day.** 28 mg over the run. 3 × 10 mg vials × $61 = **$183**. Cost per day = **$3.27**. A 10 mg vial at 500 mcg a day is 20 doses, which fits inside the four-week window with nothing wasted. **TB-500 at 2.5 mg twice a week.** 5 mg a week × 8 = 40 mg. 4 × 10 mg vials × $61 = **$244**. Cost per day = **$4.36**. Each vial is 4 doses, so exactly two weeks per vial. **Consumables.** Bacteriostatic water, insulin syringes, alcohol swabs: about $30 for a run at retail. | What is run | Eight-week materials | Per day | |---|---|---| | BPC-157 alone, 500 mcg/day, 20 mg vials | $126 + $30 = **$156** | $2.79 | | TB-500 alone, 500 mcg/day | $183 + $30 = **$213** | $3.80 | | Both, 500 mcg/day each, cheapest vial sizes | $126 + $183 + $30 = **$339** | $6.05 | | Both, 500 mcg/day each, smallest vial sizes | $252 + $183 + $30 = **$465** | $8.30 | | Both, BPC daily + TB 2.5 mg twice weekly | $126 + $244 + $30 = **$400** | $7.14 | Adding the second compound to a BPC-157-only run costs $183 over eight weeks and doubles the injections. That is the price of the only thing the pairing buys, and the one experiment that measured whether it buys anything found that it did not. None of these prices buys a verified product. There is no pharmacy channel for either compound, no monograph, and no requirement on any vendor to be accurate. A batch-specific purity test and mass-spectrometry identity report is the only thing standing between a buyer and a vial of something else, and at least one of the reports above — the man who ran 10 mg with no result and wondered whether his source was fake — is exactly that failure mode. ## Twelve weeks with a torn rotator cuff, hour by hour and dollar by dollar One case, walked all the way through, with the numbers attached and the failure conditions written down before the start. **Week 0 — what exists.** Partial-thickness rotator cuff tear confirmed on MRI. Pain 6/10 overhead, 2/10 at rest. Cannot sleep on that side. MRI already done: $400–$1,800 cash, $250–$400 typical Medicare allowable, 1 hour. Four things get written down as the baseline, because a result nobody measured is a result nobody has: pain overhead on a 0–10 scale, degrees of pain-free overhead reach measured against a doorframe, nights woken per week, and heaviest weight pressed overhead for five reps. **Weeks 1–12 — the part that actually has evidence.** Progressive loading, twice a week with a therapist for the first six weeks then once. 18 visits at $75–$150 = $1,350–$2,700, about 18 clinic hours plus 20 hours of home work. This is the arm of the plan with randomised human trials behind it, and it is also the largest line in both the money column and the hours column. Anything else is added on top of it, never instead of it. **Weeks 1–8 — the compounds, if they are run.** BPC-157 500 mcg a day and TB-500 500 mcg a day, into abdominal fat. Materials $339. Time: about 4 minutes a day for two injections, 56 days, so 3.7 hours over the run, plus roughly 20 minutes total spent reconstituting five vials. **Week 4 — first decision point.** The stopping rule, set in advance: if nights woken per week has not fallen at all by week 4 and pain-free overhead reach has not gained at least 10 degrees, the compounds stop. That is not a strict test — a rotator cuff on a good loading programme improves over four weeks anyway — but a run showing zero movement on both measures at four weeks has failed its own premise. Money saved by stopping there: $170. **Week 8 — second decision point.** Compounds end regardless. Both measures are read again. Anything that has improved from here belongs to the loading programme, which is running either way, and that is the point of ending the run while therapy continues — it separates the two. **Week 12 — the state at the end.** Running total: $1,350–$2,700 in physical therapy, $339 in materials, $400–$1,800 for the MRI, so **$2,089 to $4,839**. Patient time: about 42 hours. The expected result on the loading programme alone, from the trial literature, is substantial improvement in pain and function in most partial-thickness tears at twelve weeks without surgery. The compounds cannot be credited for that, because a single person running one arm cannot separate a treatment from the natural course. What one person can learn is whether they got a side effect, whether they tolerated it, and what it cost. **What would count as failure.** No change on either baseline measure at week 4. A new problem — swelling, worsening pain in an untreated joint, anything visual. Or pain that improves during the run and returns within two weeks of stopping, which points at irritation settling rather than tissue rebuilt. ## In United States law neither one is a medicine Neither BPC-157 nor TB-500 is an approved medicine in the United States. Neither is banned outright either. Both sit in a specific and awkward place, and the FDA page that defines it is public. Both appear on FDA's list of bulk drug substances "nominated but withdrawn" — substances that were put forward for use in compounded medicines, placed in the agency's category 2 for possible significant safety risks, and then pulled by whoever nominated them. FDA's stated concerns, in its own words, are that compounded products containing BPC-157 "may pose risk for immunogenicity for certain routes of administration" and that for the thymosin beta-4 fragment "FDA has not identified any human exposure data" and "lacks important information regarding any safety issues raised by this drug, including whether it would cause harm if administered to humans." [[embed:source:s31]] What follows from that, in plain terms: - No pharmacy can lawfully compound either one. Neither is on the 503A list that traditional compounding pharmacies work from, nor the 503B list that outsourcing facilities work from. - On 23–24 July 2026 FDA's Pharmacy Compounding Advisory Committee voted 8–6, with one abstention, in favour of allowing BPC-157 and TB-500 to be compounded, against FDA's own written recommendation. That vote is advice. It does not bind FDA, it does not make either an approved drug, and the rulemaking it triggers realistically takes eight to twelve months. - "Research use only" on a vial is a shipping label, not a legal category that makes anything safe or lawful to inject. [[embed:source:s32]] ## Both are banned in tested sport, at all times Anyone who competes under anti-doping rules — collegiate, professional, masters, national federation, Olympic pathway — is exposed, and so is anyone serving in the United States military. - BPC-157 is named in the WADA 2026 Prohibited List under S0, non-approved substances, prohibited at all times, in and out of competition. - TB-500 is named under S2.3, growth factors, as "Thymosin-ß4 and its derivatives e.g. TB-500", also prohibited at all times, in the harsher non-specified tier. - The S2.3 catch-all covers substances affecting "muscle, tendon or ligament protein synthesis/degradation, vascularisation, energy utilization, regenerative capacity" — the exact reason someone would take either one is written into the prohibition. - Strict liability applies. Intent does not matter, and who recommended it does not matter. The Canadian Centre for Ethics in Sport imposed a four-year ban on an athlete for exactly this pair. - Sanctions can be imposed with no positive test at all, on an admission, a possession finding, or a purchase record. - The Department of Defense lists BPC-157 on its prohibited supplement ingredients list and states plainly that it is not a dietary ingredient, it is an unapproved drug. [[embed:source:s33]] Off-season use is a violation. There is no window in which either compound is allowed. ## What is solid, what is a guess, and what nobody knows **Solid.** - TB-500 raised the breaking strength of a repaired rat Achilles tendon against control, 8 animals per arm, four weeks, p < 0.05. - BPC-157 improved healing in rat tendon-to-bone, ligament, muscle, sciatic nerve and spinal cord models, across many separate experiments from largely one research group. - Tested head to head in rats, the combination beat neither compound alone. - Neither is an approved medicine, neither is lawfully compoundable, and both are banned in tested sport at all times. - Doses in real use are 250 to 500 mcg a day, well below every published human dose of BPC-157, which were all milligram doses. **A guess.** - That any rat dose translates to a human dose. Scaling the standard rat dose of 10 µg/kg straight to a 70 kg adult gives about 0.7 mg a day, roughly twice what most people take. - That injecting near the injury beats injecting into abdominal fat. Nothing has compared them. - That the vial contains what the label says. Nothing requires it to. - That the two compounds are worth running together. One experiment says no, and it has the limits set out above. **Nobody knows.** - What either compound does in a person over months. The longest human exposure on record for BPC-157 is two weeks in a Phase 1 study. - Whether the immune system reacts to repeated injections of either. FDA named this as its specific concern and no one has measured it. - What happens if either is taken by someone with an undiagnosed cancer. Both are proposed to grow blood vessels, which is also what a tumour needs, and thymosin beta-4 is overexpressed in many solid tumours. - Whether the fragment sold as TB-500 does anything the full protein does, outside the one rat tendon study. For the version of this stack aimed at a worn disc and nerve pain, with ARA-290 added for the nerve itself, the mechanism table, the evidence grades and the three-compound arithmetic are set out separately. [[embed:wolverine-stack-ara-290]] [[embed:what-are-peptides-herniated-disc]] [[embed:degenerative-disc-disease]] [[embed:ara-290]] ## Sources 1. Biçer O, Adanir O, Güleryüz Y, Balci EC. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Jt Dis Relat Surg, 23 July 2026. PMID 42542926 — https://pubmed.ncbi.nlm.nih.gov/42542926/ 2. NCT07437547 — A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Pentadecapeptide BPC 157 for Accelerated Repair of Acute Grade II Hamstring Strain Confirmed by MRI. Hudson Biotech. Recruiting, started 2 February 2026 — https://clinicaltrials.gov/study/NCT07437547 3. FDA Briefing Document, Pharmacy Compounding Advisory Committee — TB-500-related bulk drug substances, July 2026 — https://www.fda.gov/media/193349/download 4. Reddit r/Biohackers — u/beach_nuts, 8 June 2026 — anecdotal, positive — https://www.reddit.com/r/Biohackers/comments/1u09ium/bpc_157_tb500_side_effect_for_65_yrs_old/oqhs3hp/ 5. Reddit r/PEDs — u/SprinklesWise9857, 11 October 2025 — anecdotal, positive, self-assessed — https://www.reddit.com/r/PEDs/comments/1o3g7qp/is_oral_bpc157_less_effective_than_injecting_it/niwej2s/ 6. Reddit r/Sciatica — u/kunukxathletix, 7 March 2026 — anecdotal, positive, sciatic pain — https://www.reddit.com/r/Sciatica/comments/1rnicr5/pinched_sciatic_nerve/ 7. X — @WovenDissent, 2026 — anecdotal, positive, elbow tendons — https://x.com/WovenDissent/status/2071612933382037588 8. X — @MuroCrypto, 31 July 2026 — anecdotal, positive, herniated lumbar disc, ran both compounds — https://x.com/MuroCrypto/status/2083184469956059529 9. Reddit r/steroids — u/SwaveyyyD, 16 July 2023 — anecdotal, positive — https://www.reddit.com/r/steroids/comments/150bge2/compounds_healing_compounds_bpc157_tb500/js5hfcw/ 10. Reddit r/steroids — u/UnusuallyTarded11, 16 March 2025 — anecdotal, positive, rotator cuff — https://www.reddit.com/r/steroids/comments/1jcmlrc/compounds_healing_compounds_bpc157_tb500_etc/mi4eq0n/ 11. Reddit r/steroids — u/MysterMumbles, 17 March 2025 — anecdotal, positive then relapse on stopping — https://www.reddit.com/r/steroids/comments/1jcmlrc/compounds_healing_compounds_bpc157_tb500_etc/mi9owhr/ 12. X — @drmarlonperalta, 4 June 2026 — anecdotal, positive, ten years of low back pain from a herniated disc — https://x.com/drmarlonperalta/status/2062565899714925044 13. X — @AJA_Cortes, 26 May 2024 — anecdotal, positive, L5-S1 flare, writer flags placebo himself — https://x.com/AJA_Cortes/status/1794522474702336108 14. Reddit r/steroids — u/MjolnirCurls, 28 February 2018 — anecdotal, no effect — https://www.reddit.com/r/steroids/comments/7zy7yi/compound_experience_saturday_bpc157/duz790a/ 15. Reddit r/backpain — u/ImNotSchema, 19 August 2025 — anecdotal, no effect, ran both compounds — https://www.reddit.com/r/backpain/comments/1mu96us/hlab27_sacroiliitis_on_mri_vs_disc_obliteration/ 16. Reddit r/PEDs — u/Itchy_Brain6340, 9 October 2023 — anecdotal, no effect, ran both compounds — https://www.reddit.com/r/PEDs/comments/173pdv4/compounds_to_help_articular_cartilage_fissure_in/ 17. X — @prax1s_mm, 30 July 2026 — anecdotal, no effect, third separate attempt, ran both compounds — https://x.com/prax1s_mm/status/2082901582627184835 18. X — @LtCrandog, 30 July 2026 — anecdotal, no effect over ten years of use — https://x.com/LtCrandog/status/2082758463407473109 19. Reddit r/Peptidesource — u/TheAwkwardEmu, 25 July 2026 — anecdotal, no effect at six weeks — https://www.reddit.com/r/Peptidesource/comments/1v6e4g2/need_help_deciding_between_kpv_low_dose/ 20. Reddit r/moreplatesmoredates — u/Cr1ms0nSlayer, 8 May 2025 — anecdotal, no effect across two vendors — https://www.reddit.com/r/moreplatesmoredates/comments/1kfp3uf/does_bpc157_increase_recovery_between_workouts/mr860tt/ 21. Reddit r/steroids — u/jlthreequarters, 17 March 2025 — anecdotal, no effect, injected near the knee — https://www.reddit.com/r/steroids/comments/1jcmlrc/compounds_healing_compounds_bpc157_tb500_etc/mi6t9l6/ 22. Reddit r/Biohackers — u/Trofas27, 16 June 2026 — anecdotal, effect then loss of effect — https://www.reddit.com/r/Biohackers/comments/1u7ddu1/i_know_some_will_disagreebut_new_batch_of_bpc_157/ 23. Reddit r/backpain — u/Miserable_Fan1984, 16 September 2024 — anecdotal, got worse, herniated disc, ran both compounds — https://www.reddit.com/r/backpain/comments/1fi50ar/bpc_157_and_tb_500_for_herniated_disc/ 24. Reddit r/PEDs — u/Illustrious_Buy_6545, 18 January 2026 — anecdotal, got worse in an untreated joint — https://www.reddit.com/r/PEDs/comments/1qftcul/bpc157_gone_wrong/ 25. Reddit r/Biohackers — u/cityhunterspeee, 20 February 2026 — anecdotal, got worse, vision, ran a blend of both — https://www.reddit.com/r/Biohackers/comments/1ra2m3p/1_month_of_bpc157_tb500_blend_reviewblurry_vision/ 26. Reddit r/climbharder — u/WeenieLoft, 22 February 2024 — anecdotal, got worse, swelling at the treated finger — https://www.reddit.com/r/climbharder/comments/1axf2aa/my_experience_case_study_recovering_from_an_a2/ 27. Nationwide Peptides — BPC-157 and TB-500 research-chemical listings, prices read 4 August 2026 — https://www.nationwidepeptides.com/products/bpc-157-peptide/ 28. FDA — Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks, current as of 22 April 2026 — https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks 29. STAT News, 23 July 2026 — FDA advisory panel narrowly votes to allow compounding of unapproved peptides — https://www.statnews.com/2026/07/23/fda-panel-okays-peptides-compound-pharmacies-bpc-157-kpv/ 30. World Anti-Doping Code International Standard — Prohibited List 2026, effective 1 January 2026 — https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf 31. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med, 12 April 2026. PMID 41966639 — https://pubmed.ncbi.nlm.nih.gov/41966639/ 32. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. Am J Sports Med, January 2026. PMID 41476424 — https://pubmed.ncbi.nlm.nih.gov/41476424/ 33. Reddit r/steroids — u/RGJJBrwn2022, 16 March 2025 — anecdotal, positive, ran both compounds — https://www.reddit.com/r/steroids/comments/1jcmlrc/compounds_healing_compounds_bpc157_tb500_etc/mi4uao6/ 34. Reddit r/Biohackers — u/hraww, 9 April 2026 — anecdotal, positive, ran both compounds — https://www.reddit.com/r/Biohackers/comments/1sgf3q0/bpc157_and_tb500_weekly_update/ 35. Reddit r/steroids — u/Blahblahblurred, 16 March 2025 — anecdotal, positive, ran both compounds — https://www.reddit.com/r/steroids/comments/1jcmlrc/compounds_healing_compounds_bpc157_tb500_etc/mi4iwuk/